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ABSTRACT 
THE RAG2 C TERMINUS PARTICIPATES IN REPAIR PATHWAY CHOICE IN 
VIVO AND SUPPRESSES LYMPHOMAGENESIS 
Vered Gigi 
Dr. David B Roth 
DNA double-stranded breaks (DSBs) can be repaired by several mechanisms, 
including classical NHEJ (c-NHEJ) and a poorly defined, error-prone process 
termed alternative NHEJ (a-NHEJ). How cells choose between these alternatives 
to join physiologic DSBs remains unknown. Here we show that deletion of 
RAG2's C-terminus allows a-NHEJ to repair RAG-mediated DSBs in developing 
lymphocytes from both c-NHEJ-proficient and c-NHEJ-deficient mice, 
demonstrating that the V(D)J recombinase influences repair pathway choice in 
vivo. Analysis of V(D)J junctions revealed that, contrary to expectation, junctional 
characteristics alone do not reliably distinguish between a-NHEJ and c-NHEJ. 
These data suggest that a-NHEJ is not necessarily mutagenic, and may be more 
prevalent than previously appreciated. Whole genome sequencing of lymphomas 
arising in a p53-/- mouse bearing a C terminal RAG2 truncation reveals evidence 
of a-NHEJ and also of aberrant recognition of DNA sequences resembling RAG 
recognition sites. The ability to recognize these sites is not because of specificity 
relaxation due to the lack of the RAG2 C terminus but probably other potential 
mechanisms that should be further investigated. 
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CHAPTER 1 
INTRODUCTION	  
 
Misrepair of double-stranded breaks (DSBs) creates structural genomic lesions 
(deletions, chromosome translocations, duplications, and inversions), which can 
fuel oncogenic transformation (1,2). The need to inhibit such events and maintain 
genome integrity is very clear. However, how cells manage to do so is not.  
Resolution of DSBs is a complex cascade of events influenced by the stimulus 
that originated the break (e.g. nucleases vs radiation) and the environment in 
which it was generated (e.g. cell cycle phase, chromatin status). Such a degree 
of complexity is inherently error-prone, however, cells have evolved to be very 
efficient in faithful repair of DSBs. There are three main repair mechanisms to aid 
in joining the broken ends: Homologous Recombination (HR), classical Non 
Homologous End Joining (c-NHEJ) and alternative NHEJ (a-NHEJ). While the 
first two are well defined, our understanding of a-NHEJ is still in its infancy.  
1.1 DNA Repair mechanisms 
 
Homologous recombination 
The joining of DSBs by HR is error-free since it copies the missing genetic 
information from an undamaged sister chromatid and as such only functions in 
late S phase when a sister chromatid is available (3). It is considered the best 
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repair mechanism to protect against mutagenic outcomes from DNA damage 
(Fig. 1.1). HR repair is initiated via DSB detection and binding by the MRE11-
RAD50-NBS1 (MRN) complex (4). This step promotes resection together with 
CtBP-interacting protein (CtIP; CtBP = C-terminal binding protein), to generate 
short 3'-single-stranded-DNA (ssDNA) and then long ssDNA with the help of 
Exo1 and the BLM proteins (4). ssDNA is immediately coated with replication 
protein A (RPA) (4,5). Following is displacement of the RPA A by the BRCA2-
PALB2 complex to create RAD51 nucleation onto ssDNA (6). The RAD51 
nucleoprotein filament then invades into a similar or identical DNA duplex forming 
a displacement loop (D-Loop). A DNA polymerase then extended the invading 
strand creating a Holliday junction. The second end of the broken chromosome 
(non-invading strand) anneals to the complementary strand of the donor DNA 
molecule, resulting in a second Holliday junction. Once DNA synthesis and 
ligation of both strands is completed, the HJs are resolved in order to complete 
repair (7).  
 
Classical Non Homologous End joining 
Unlike HR, c-NHEJ is active throughout the cell cycle (though favored in the G1 
phase) and, as its name suggests, is not dependent on sequence homology for 
repair (8). In a simplistic view, c-NHEJ allows direct ligation of two DSBs. 
Nevertheless, more than often, the breaks are not ligatable, requiring a degree of  
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Figure	  1.1	  	  DSBs	  repair	  pathways.	  Homologous	  Recombination	  (HR)	  was	  adapted	  and	  
modified	  from	  Rémi	  Buisson	  &	  Jean-­‐Yves	  Masson	  Nature	  Structural	  &	  Molecular	  Biology	  
2010.	  Classical	  NHEJ	  (C-­‐NHEJ)	  and	  Alternative	  NHEJ	  (A-­‐NHEJ)	  were	  adapted	  and	  
modified	  from	  Deriano	  L	  &	  Roth	  DB	  Annu.Rev.Genet	  2013.	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processing leading to nucleotide loss and/or addition. Therefore, c-NHEJ is 
considered ʻerror proneʼ. However, on a genomic level, c-NHEJ appears to limit 
genomic damage and suppress tumorigenesis (9,10,11,12). c-NHEJ repairs 
DSBs that are either generated inadvertently (e.g irradiation) or ones that are 
physiologically important for development like in the process of Variable (V) 
Diversity (D) Joining (J) (V(D)J) and Class Switch Recombination (CSR) in the 
immune system. A lot of our understanding the c-NHEJ in the mammalian system 
comes from various manipulations carried out in these two systems.  
c-NHEJ is initiated with the binding of the Ku70/80 heterodimer (KU) and the 
MRN complex to the broken ends (Fig.1.1). The KU complex is the first to bind to 
the DNA on the basis of its abundance (estimated at 400,000 molecules per 
cell) and its binding capacity ( 10−9 M)(13,14). The KU:DNA complex on each 
end serves as a ʻtool beltʼ for other proteins to dock onto in preparation for joining 
(8). Though there is no evidence for a single recruitments cascade of proteins to 
the KU:DNA complex to facilitate repair (15,16), it is likely that the catalytic 
subunit of DNA-dependent protein kinase (DNA-PKcs) follows to create the DNA-
PK holoenzyme (DNA-PK) (17). This step leads to phosphorylation events 
mediated by the DNA-PK resulting in diverse DNA end processing by the Artemis 
nuclease to prepare ends for ligation (18,19). Often but not obligatory there is an 
involvement of the pol X polymerase family. Poly μ, λ and terminal 
deoxynucleotidyltransferase (TdT) are capable of binding to the KU:DNA 
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complex and insert short templated or non-templated neucleotides (15,20). 
Completion of the repair is catalysed by a complex consisting of X-ray repair 
cross-complementing protein 4 (XRCC4), DNA ligase IV and XRCC4-like factor 
(XLF) (21-24). It is important to mention that some factors of c-NHEJ are 
conserved throughout evolution and are essential (Ku70/80, XRCC4Ligase 4 and 
XLF) for repair while others can be dispensable depending on the context.  For 
example, Artemis is necessary to generate coding joints as it opens the hairpin 
but it is dispensable for signal joints (25). 
Great flexibility exists in this repair both in terms of the breaks it can handle and 
in the ligation step (18,19,26,27). This is beautifully demonstrated in V(D)J 
recombination. First, the c-NHEJ machinery needs to join two very different ends 
(blunt and hairpin sealed, reviewed later). Second, in the case of the hairpin 
ends, although they are the same starting substrate, the joining junctions at the 
end of the repair are entirely different. This c-NHEJ flexibility is beneficial for the 
organism but complicates our efforts for understanding processes that occur in its 
absence. 
c-NHEJ is considered error prone suggesting its involvement in genomic lesions. 
However, studies of genomic aberrations in various tumors cannot unequivocally 
prove or disprove this statement. On the one hand, mice deficient for both c-
NHEJ factors and the p53 develop lymphomas very rapidly with recurrent 
translocations (9,10) suggesting that c-NHEJ suppresses tumorigenesis. On the 
other hand, p53 deficient or Ataxia telangiectasia mutant (ATM) mice, in which c-
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NHEJ is functional, also develop lymphomas with different translocations (28-30). 
Hence, the contribution of c-NHEJ to such events is still an open question. 
 
Alternative Non Homologous End joining 
A third repair mechanism has emerged in the last decade but our understanding 
of it is still a work in progress (Fig. 1.1). As a testimony are the multiple names 
given to it:  Alternative NHEJ (a-NHEJ; which will be used throughout this body of 
work), Backup NHEJ (B-NHEJ) or microhomology-mediated end joining (MMEJ).  
a-NHEJ was discovered in cells deficient for c-NHEJ where transfected, 
linearized plasmids were able to recircularize and be recovered from cells so that 
their joining properties could be evaluated (31,32). Aside from clearly showing 
that c-NHEJ-independent end joining is present it also started shaping our 
thoughts of what a-NHEJ might look like in terms of joint structure. Unfortunately 
the analysis of junctions in c-NHEJ-deficient settings emphasized the joints that 
looked different from those formed by c-NHEJ, underestimating the fraction that 
did resemble cNEHJ joints. Moreover, some results were not consistent across 
different systems (31,33,34) or different c-NHEJ deficiencies (31). These issues 
in turn raised the possibility that a-NHEJ might be a collection of different 
pathways rather than a single one.  
A repair pathway can be evaluated through different lenses and in the case of a-
NHEJ it is concentrated on three criteria: the quality of the end joining, potential 
factors and its predisposition to genomic instability.  
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 End joining quality: simply put, any characteristics of joined ends that 
deviate from typical c-NHEJ are considered a-NHEJ. This is a very problematic 
criterion because c-NHEJ, as mentioned earlier, shows a diverse spectrum of 
joining products. Nonetheless, finding of extensive deletions, microhomologies 
and long insertions became viewed as indications of alternative joining 
(35,36,31,33). In common practice, as long as one characteristic can be 
demonstrated it is considered a-NHEJ. The great challenge with this criterion is 
how we interpret such results. For instance, in a Ku70-deficient cell line the 
length of microhomology and median length of deletion in translocation events 
were not different from those in wild-type cells where c-NHEJ is present (37). 
Hence, we cannot be certain that the junctional features associated with a-NHEJ 
are really a reliable criterion to distinguish between classical and alternative 
NHEJ.  
Potential Factors: To date no one specific factor associated with a-NHEJ 
has been described. Moreover, one can find contradictory results regarding a 
potential factor and its contribution to a-NHEJ (38). Most factors are associated 
with other DNA repair pathways adding to the complexity of elucidating this 
repair. The potential factors are almost a “tit for tat” of the c-NHEJ machinery. 
Poly [ADP-ribose] polymerase 1 (Parp1) is thought to compensate for Ku80 
deficiency and bind to the broken ends to initiate the repair process (39-42). This 
is followed by end resection via the CtBP-interacting protein (CtIP) and the Mre11 
nucleases (37,43,44). This resection creates the extensive deletions observed in 
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order to uncover stretches of microhomology that can anneal. Subsequently, gap 
filling by a DNA polymerase and ligation via the XRCC1/ligase 3/1 complex 
completes the repair process (39,45,46).  
It is still unclear whether, how and to what degree these factors interact with each 
other in order to achieve this repair. It is plausible that there are multiple ways for 
this cascade of events to take place. Additionally, for the most part, these factors 
were tested in the absence of one of the c-NHEJ proteins. Hence it is also a 
possibility that these potential factors might interact with part of the c-NHEJ 
cascade to complete repair (47). 
 Predisposition to genomic instability: This functional assessment of a-
NHEJ was determined due to tumor studies done in c-NHEJ-deficient mice 
(9,10). Mice deficient for p53 and any either of the following: Ku80-/-, Ligse4-/- or 
Xrcc4-/-, developed rapid pro-B cell lymphomas with recurrent translocations 
involving the IgH locus and the c-myc oncogene (9,10). As the c-NHEJ repair is 
disabled in these mice it was concluded that a-NHEJ repair disrupts the integrity 
of the genome leading to tumorigenesis. Further studies using various cell lines 
deficient for c-NHEJ supported that conclusion by showing an increase in 
translocation frequencies (38,48,49). This was followed by research 
demonstrating the involvement of CtIP and ligase3, potential a-NHEJ factors, in 
mediating such chromosomal translocations (37,46). However, contrasting 
results were obtained from mice and cells lacking Parp1 concluding that this 
factor is important for genome stability (50,51). Lastly, involvement of a-NHEJ 
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was also documented in human tumors where a decrease in Ku80 and increase 
in Parp1 or Ligase 3 were observed (52-54). It is important to note that the quality 
of junctions seen in translocation events from the different systems could not 
consistently be distinguished from junctions mediated via c-NHEJ repair. This 
issue nicely illustrates the problem we are facing with the current criteria that 
define a-NHEJ. Moreover, other genomic aberrations such as deletions, 
duplications and inversions were not systematically studied in these systems to 
evaluate the extent of a-NHEJ contribution to genomic instability.  
 
Based on the above criteria a-NHEJ was evaluated also in cultured cells 
proficient for c-NHEJ repair and was shown to be active (36,46,55). This 
suggested that mechanisms might exist to limit its usage, presumably to preserve 
genomic integrity and suppress tumorigenesis. Whether a-NHEJ is another repair 
pathway, a collection of sub pathways, or just the extreme end of the c-NHEJ 
flexibility is yet to be determined.  
 
1.2 DNA repair and pathway choice 
How cells control choice of a particular pathway (homologous recombination, c-
NHEJ, or a-NHEJ) for repair of a given DSB is a question of intense current 
interest. The prevailing notion is that there is an active decision between the 
different repair pathways. Early experiments showed that an extra chromosomal 
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substrate, when transfected into mammalian cells, could be repaired either by HR 
or NHEJ, indicating that both repair pathways are available and compete with 
each other (56). Misrepair of a DSB is associated with a variety of pathologies 
(e.g immunodeficiency) and increased cancer susceptibility. What criteria 
channels a certain DSB from one repair pathway to another would be beneficial 
in understanding tumor etiology, evolution and in developing targeted therapy 
against it.  
Different pathways can repair DSBs, which is determined in part by the cell cycle 
phase in which the breaks occurred. Through the cell cycle phases the cell 
controls availability of DSBs sensors/repair factors and presence of a 
homologous template that is critical for HR. However, the stage of the cell cycle 
is not sufficient for correct repair as we know that c-NHEJ factors exist 
throughout the cell cycle and homologous chromosome, that can serve as a 
template and HR factors, exist in the G0/G1 stage. Moreover, the recruitment of 
factors from both pathways to DSBs can happen simultaneously and 
independently from each other both in G1 and S/G2 phases (57).  
It is thought that end resection is one critical step that can commit cells to HR 
rather than c-NHEJ and this is mediated via the CtIP/MRN complex (58,59). 
Whether in the G1 or S/G2 phase, recruitment of CtIP would lead to homology-
mediated repair; a-NHEJ in the G1 phase a-NHEJ/HR in the S/G2 phase. Hence, 
different mechanisms exist to regulate CtIP activity. In the S/G2 phase CtIP 
activity is increased via Cyclin dependent kinase 1 (CDK1) to promote end 
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resection for HR (4). In the G1 phase, histone H2AX prevents CtIP end resection 
in lymphocytes (58), and 53BP1 inhibits BRCA1, a CtIP interacting protein, from 
accumulating on DSBs to suppress end resection favoring NHEJ (59). However, 
a different study showed that BRCA1 stabilized Ku80 binding to chromosomal 
DSBs resulting in high fidelity NHEJ repair (60). In addition to end resection, 
maintaining an overall balance between HR and NHEJ factors and their activity is 
also important for correct repair. Deficiency in c-NHEJ factors shifts the balance 
in favor of HR/a-NHEJ (40,48,61,62) while decrease in HR proteins in G1 phase 
supports NHEJ repair (63). For example, DNAPKcs levels are constant 
throughout the cell cycle yet its activity is not. Phosphorylation of residue 2056 in 
G1 is important for proper NHEJ and is diminished in S phase, inhibiting this 
repair (64). It is important to note that some repair factors are needed for both 
repair machineries adding another layer of complexity (43,60,64) 
 
Most of our knowledge refers to the choice between HR and NHEJ as a whole. 
However, within NHEJ we distinguish c-NHEJ vs a-NHEJ. Several proposals 
exist regarding this pathway choice. Some a-NHEJ are mediated via 
microhomology, positioning short end resection by the MRN/CtIP complex as a 
regulator of that pathway (37,43). Similarly, 53BP1 inhibits such resection 
therefore promoting c-NHEJ (65,66). In the V(D)J recombination process, the 
RAG complex was shown to shuttle broken ends away from a-NHEJ to the c-
NHEJ in vitro (36). 
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However, most attempts to study this pathway choice were investigated in the 
absence of one or more critical c-NHEJ repair factors and often using an artificial 
readout (31,33,35). These genetic approaches are beneficial once a comparison 
between defined systems has been investigated. The best deficnition of a-NHEJ 
to date is ʻrepair in the absence of c-NHEJʼ. Hence, how can one study a choice 
between two pathways when one is dependent on the otherʼs absence? This 
hampers our attempts to understand mechanisms of pathway choice, as the 
missing factor might itself be involved. Another caveat is that these approaches 
may bias the type of junctions produced by a-NHEJ. For instance, according to 
some research, Ku80 is thought to protect the ends from degradation (33). 
Hence, disabling end protection mechanisms can lead to excessive deletion or 
production of long single-stranded tails that are not necessarily a true feature of 
a-NHEJ. Lastly, it has been shown that experimental knockouts can generate 
secondary mutations and adapt to the deficiency (67). As a result we must find a 
system where the c-NHEJ factors are present and the stimulus of DSBs is 
physiological. One such system is the V(D)J recombination process where a-
NHEJ repair has been shown to be very active in the presence of c-NHEJ repair 
machinery (36).  
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1.3 V(D)J recombination 
V(D)J recombination provides a tractable and physiologically relevant system in 
which to explore end-joining pathways and regulation of pathway choice. This 
process is responsible for the development and the diversity of our B and T cells 
that grant us with a functional and robust immune system. In a tightly regulated 
process, our DNA is purposefully cleaved, ʻrearrangedʼ and then rejoined to 
create the immunoglobulin Ig and T cell receptor (TCR) while maintaining 
genome integrity (8,68,69). There are three Ig (IgH, IgK, Igλ) and 4 TCR loci 
(TCR α/β/γ/δ) that are located on different chromosomes. IgH and TCRβ/γ 
undergo 2 sequential rounds of recombination: D-J followed by V-DJ to generate 
a functional rearrangement. After a successful attempt, IgK/λ and TCRα/δ carry a 
single V to J recombination event. A successful rearrangement results in a 
functional BCR/TCR that then undergoes positive and negative selections that 
determine its faith (survival vs apoptosis).  
The process begins when the V(D)J recombinase, comprised of the protein 
products of recombination activating genes 1 and 2 (the RAG1/2 proteins, RAG), 
cleaves the DNA between an antigen receptor coding segment (V/D/J) and a 
flanking recombination signal sequence (RSS)(69) (Figure 1.2). RSS consist of 
conserved heptamer (CACAGTG) and less conserved nonamer (ACAAAAACC) 
sequences separated by a non-conserved spacer of 12 or 23 nucleotides. 
Normally a synapsis of a 12/23 RSS pair is required to form DSBs. It is thought 
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that the synaptic complex formation occurs in a sequential manner where the 
RAG complex binds and perhaps nicks one RSS and then captures the other 
RSS to form the synaptic complex (70-72). Following is nicking of the partner 
RSS culminating in coupled cleavage of both RSSs via a transesterification 
process through the 3′-OH group exposed by nicking. This process produces two 
covalently sealed (hairpin) coding ends and two 5′-phosphorylated blunt signal 
ends (69,73). Lastly is a joining step that is facilitated by the RAG post cleavage 
complex (PCC) and the c-NHEJ repair machinery (36,69,74). The coding ends 
undergo a degree of processing starting with the opening of the hairpin by the 
DNAPK-Artemis complex (19). This can be succeeded by a loss and/or insertion 
of few nucleotides. Insertions are of two types: ʻPʼ (Palindromic) and ʻNʼ (Non-
Templated) nucleotides. The first are the result of an asymmetrical opening of the 
hairpin by Artemis and are a complementary copy of the termini (75). The second 
are insertions of non-templated nucleotides mostly by the TdT polymerase (76). 
A ligation step mediated by the XRCC4/Ligase4 complex follows to generate a 
coding joint (CJ) representing the rearranged variable regions of antigen receptor 
genes. In contrast to coding ends, signal ends are slower to repair and are blunt 
ligated with rare instances of a few nucleotides insertions or deletion (77-80). For 
the most part they form an excised circular molecules that are lost with cell 
divisions. Functionally, signal joints were thought to be immunologically inert but 
some studies have shown that they can be recleaved and reinserted into the 
genome disturbing its integrity (81,82).  
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Figure	  1.2	  A	  simplified	  overview	  of	  the	  V(D)J	  recombination	  process.	  The	  RAG	  complex	  
(yellow	  circles)	  recognizes	  and	  binds	  the	  RSSs	  (triangles).	  Formation	  of	  a	  synaptic	  
complex	  and	  culmination	  of	  the	  cleavage	  reaction.	  Subsequent	  is	  processing	  of	  the	  
coding	  ends	  and	  then	  ligation	  to	  generate	  a	  coding	  joint	  and	  a	  signal	  joint.	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Another, atypical type of end joining was observed in the late 80ʼs where a signal 
end joined a coding end, generating a hybrid joint (HJ)(83). These joints clearly 
do not result in functional antigen receptor rearrangements but can be used as a 
marker of improper recombination. For example, in RAG2 Core mice (amino acid 
1-352), which are devoid of the C terminus, there is an increase in HJ formation 
vs wild-type mice implying its importance in regulating proper recombination and 
maintaining genomic information (84). 
There are multiple levels of regulation to ensure proper recombination. First, 
there is lineage specificity; Ig loci rearrange in B cells and TCR in T cells. This is 
achieved by actively transcribing only the locus that needs to rearrange (85,86). 
Second, recombination is carried out in cis rather than in trans to eliminate 
chromosomal translocation (87). Third is the control of RAG1/2 expression. While 
RAG1 can be detected throughout the cell cycle, RAG2 is restricted to the G0/G1 
phase due to a protein degradation signal (88). RAG1 cannot create DSBs 
without RAG2 ensuring that they do not occur in the S/G2 phase when replication 
occurs. Last but not least are epigenetic markers. Though H3K4me3 is not 
essential for recombination it is an important determinant of RAG2 localization 
and efficient recombination (89,90). Interfering with any of these regulations and 
others might decrease V(D)J recombination efficiency and could also lead to 
illegitimate recombination that can be very deleterious to the genome integrity. 
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Illegitimate V(D)J recombination  
DNA cleavage and joining during the V(D)J process must be tightly regulated to 
prevent genomic lesions. A role for V(D)J recombination in such events was 
hypothesized when translocations in certain tumors showed a fusion of the 
antigen receptor gene to another region of DNA (91,92). Since then, various 
Illegitimate V(D)J recombination events have been well documented in the 
literature both in mice and humans (93-97).  
These events can be categorized into five groups (Fig. 1.3): 
1) Joining of bona fide RSSs in trans rather than cis. In such rearrangements 
RSSs from loci on different chromosomes recombine and create a translocation. 
2) Joining of a bona fide RSS to an RSS-like sequence outside of the antigen 
receptor loci (termed cryptic RSS, cRSS).  
3) Joining of two cRSSs.  
4) Joining of a bona fide RSS to a random DSB that was generated in a process 
not related to V(D)J recombination (referred to as end donation). 
5) Transposition. DNA cleavage by the RAG complex creates a 3ʼ hydroxyl group 
(OH) on a signal end. This reactive group can ʻattackʼ a target DNA and 
transpose the signal end into that region (81). These events are very rare in vivo 
because they can only be identified if the signal end retains its sequence (98). 
 
Aside for group one, which is an obligatory trans rearrangement, all the rest can 
happen either in cis or trans. Genomic structural variants (SVs) such as 
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translocations, deletions, inversions and amplifications generated via these 
illegitimate processes have all been reported (91-95,97). The different types of 
events are also telling in regards to the mechanism that might promote them. In 
groups 1 and 4 where authentic RSSs are used we can assume that there was 
no mistake in RSS sequence recognition. This is in striking contrast to groups 
2&3 where the RAG complex misrecognizes a sequence to be an RSS and at 
minimum binds and cleaves it.  
Outcomes of V(D)J aberrant events are detrimental to a cell and to an organism 
as a whole. They can impede the development of the immune system and 
decrease its diversity. For example, inter-locus rearrangements between the TCR 
beta on chromosome 6 and TCR gamma on chromosome 14 can lead to a 
translocation that abolishes functional TCR rearrangements (99,100) resulting in 
cell death (101). 
More hazardous are illegitimate V(D)J recombination events that participate in 
pathogenesis of lymphomas. A recent study found that almost 40% of SVs 
detected in ETV6-RUNX1–positive Acute Lymphoblastic Leukemia (ALL) are a 
consequence of such events, serving as a major mechanism in this tumor 
progression (97). Also, end donation events (group 4) are implicated in 
translocations found in 30-40% of follicular and mantle cell lymphomas (100,102).  
So far there is no standardized scheme to evaluate cRSS. The minimal 
requirement is to have a ʻCACʼ sequence in the vicinity of the break (96).  
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Figure	  1.3	  illegitimate	  V(D)J	  recombination	  scenarios.	  Group1;	  recombination	  between	  
two	  bona	  fide	  RSSs	  that	  are	  on	  different	  chromosomes	  resulting	  in	  translocation.	  The	  
same	  scenario	  can	  present	  itself	  in	  cis.	  For	  example,	  Db1-­‐Db2.	  Triangles	  are	  12/23	  RSS	  
Group2;	  recombination	  between	  bona	  fide	  RSS	  and	  a	  cRSS.	  Again	  this	  can	  happen	  in	  cis	  
or	  trans.	  The	  oncogene	  is	  used	  as	  a	  demonstration	  for	  the	  deleterious	  effect	  of	  such	  
event.	  Light	  blue	  triangle	  represents	  cRSS.	  Group	  3;	  recombination	  between	  two	  cRSSs;	  
the	  cis	  configuration	  is	  presented	  but	  it	  can	  also	  happen	  in	  trans.	  Triangles	  represent	  
cRSSs.	  Group	  4;	  recombination	  between	  a	  bona	  fide	  RSS	  and	  a	  random	  break,	  again	  in	  
cis	  or	  trans.	  Group	  5;	  transposition	  event	  mediated	  by	  12/23	  signal	  ends,	  which	  can	  
interrupt	  genetic	  information.	  In	  blue	  are	  the	  direct	  repeats	  of	  the	  targeted	  sequence.	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Several other features, if present, can be used to strengthen involvement of 
V(D)J recombination: nonamer-like sequence within 12/23 bp of the heptamer, 
and presence of ʻNʼ or ʻPʼ nucleotides at the joint. Lewis et al showed that a 
cryptic heptamer, which is sufficient for recombination, could be found every 
600bp in the mouse genome illustrating the great potential of illegitimate V(D)J 
recombination(96). 
 
1.4 V(D)J recombination and repair pathway choice 
Efficient and faithful end joining in the V(D)J process is critical to ensure a 
diverse immune system and to prevent both genome instability and 
lymphomagenesis. The process, as outlined earlier, is dependent on c-NHEJ 
machinery. Mice deficient for c-NHEJ factors, if not embryonic lethal (103,104), 
exhibit developmental block at the pro-B/pro-T cell stage accompanied by severe 
lymphopenia because they cannot complete the antigen receptor rearrangements 
(105-108).  
On the face of it, V(D)J recombination has tremendous potential for errors. It 
introduces DSBs in large numbers of lymphocyte progenitors, and, through end-
to-end joining, generates megabase-sized modifications of the genome (69). The 
system has evolved to minimize aberrant events. For example, the C-terminus of 
RAG2 is evolutionarily conserved and necessary for proper recombination 
(28,36,74,99,109,110). Moreover, this region is important for the stabilization of 
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the post cleavage complex, as seen in biochemical studies, possibly to ensure 
that the ends are shuttled to the c-NHEJ rather than the a-NHEJ repair pathways 
(74,84). 
Our understanding of ʻclassicalʼ NHEJ has relied heavily on determining 
requirements for coding and signal joint formation in V(D)J recombination and 
repair of radiation-induced DNA breaks. Because exposure to a different suite of 
enzymes and repair ʻplatformsʼ is likely to affect the fine-structure of the repair 
junctions, the available comprehensive analyses of V(D)J recombination 
outcomes collected over the last thirty years provide an ideal basis by which to 
explore and define alternative NHEJ. In this system the DSBs are physiological 
rather than artificial, the breaks are tractable and we can assess the quality of 
both non-processed and processed end joining represented by signal and coding 
joints respectively. Previous work in the Roth lab suggests that it might be 
possible to alter the end-joining environment encountered by broken DNA ends 
by only mutating RAG1/2 that are extrinsic to the c-NHEJ repair pathway (36,74). 
Hence, this can provide a very ʻcleanʼ system to test the junctional features 
associated with a-NHEJ without modifying repair factors. Moreover, these 
mutants can be used to investigate whether a-NHEJ predisposes to 
tumorigenesis. If the increase in a-NHEJ observed with extrachromosomal 
substrate holds true in vivo, then these mice should develop lymphomas with 
genomic lesions mediated via a-NHEJ.  
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CHAPTER 2 
RAG2 Mutants Alter DSB Repair Pathway Choice In Vivo and 
Illuminate The Nature of ʻalternative NHEJʼ 
 
In order to look at repair pathway choice in a non-perturbed fashion we needed a 
system that does not modify the end joining factors. Our previous work suggests 
that it might be possible to alter the end-joining environment encountered by 
broken DNA ends by only mutating RAG1/2 that are extrinsic to the c-NHEJ 
repair pathway (36,74). Indeed, a particular C-terminally truncated RAG2 mutant 
termed FS361, identified in our lab, allows coding ends to abnormally access a-
NHEJ (36). This was assessed using RAG expression vectors transfected into 
fibroblasts along with an extrachromosomal substrate specifically designed to 
detect joints bearing both excessive deletion and microhomologies that have 
been considered characteristic of such repair (35,36,68,111). This implies that 
RAG2's C-terminus is important for control of pathway choice, at least in this 
artificial system.  
 
Focus on RAG2 is additionally supported by studies in which the consequences 
of germline mutations in the RAG2 C-terminus have been examined in whole 
mice (28,99,110). Though not addressed directly in those reports, the 
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recombinant V(D)J junctions that were observed raised the possibility that each 
of the C-terminal mutations may have had an impact upon pathway choice. 
Hence, to seek definitive evidence of functional alternative pathways, specifically 
a-NHEJ, without changing components of c-NHEJ we generated homozygous 
knockin mice bearing the FS361 mutation (RAG2FS/FS) that exhibited the highest 
a-NHEJ signal among those tested in transfection studies. In addition to 
establishing physiological relevance of pathway choice in vivo, this minimally-
manipulated, physiologically relevant system is ideally suited to investigate the 
hypothesis that a-NHEJ is error-prone and makes a disproportionate contribution 
to oncogenic genome rearrangement.    
 
 
 
 
 
 
 
 
 
 
 
 
	  
	  
24	  
Materials and Methods 
Mice 
We obtained wild-type C57BL6 (Taconic), Ku80 KO (The Jackson laboratory, 
108), RAG2 KO (The Jackson laboratory) and RAG2C/C which we renamed 
RAG2del352/del352 (112).  RAG2FS/FS mice were generated by Ingenious Targeting 
Laboratories as described in figure S1. The nucleotide sequence of the entire 
RAG2 ORF was verified by sequencing genomic DNA from somatic tissues of the 
knockin mouse. Rag2FS/FS and RAG2del352/del352 were bred with Ku80 KO mice to 
generate doubly deficient mice. Genotyping of all mice was performed by PCR of 
tail DNA as described (108,112). The animalsʼ care was approved by UPenn 
Institutional Animal Care and Use Committee (IACUC) Protocol # 803893 
Flow cytometry 
Cells from thymus, bone marrow and spleen were obtained from the indicated 
genotypes and stained for B cell (B220, CD43, IgM) and T cell (CD4, CD8, 
thy1.2, TCR beta, CD25, CD44) markers. FACS analysis was done using the BD 
LSR II and FlowJo software. 
PCR for CJs, SJs and Interchromosomal rearrangements  
Genomic DNA from thymus and BM were prepared from 6-9 week old mice for 
wild-type, RAG2FS/FS and RAG2del352/del352 characterization and 4 week old mice 
for joints from Ku80 deficient backgrounds. Genomic DNA for coding joints (CJ, 
200 ng) or signal joints (SJ)/interchromosomal (500 ng) were amplified by PCR. 
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CJ/SJ primers were described previously (110) aside from Vb10 SJ, Vh7183 CJ 
that are described below. For interchromosomal rearrangements we used nested 
PCR with primers described below. All PCR products were cloned using the TA 
cloning kit. For SJ, single clones were subjected to PCR with TOPO TA primers 
and products were then digested with ApaL1 to detect precise joints. Plasmid 
DNA from resistant SJs clones, all CJs and interchromosomal rearrangement 
clones were prepared and Sanger sequenced. 
Interchromosomal rearrangement primers 5ʼ-3ʼ: 
Dd2 F1    CAAGCATTAGACAGTAAGTACCCAG 
Dd2 F2    GCCAACCACTTTGATAGTCTGTGGCTTG 
Db1 R1    GAGTAATCGCTTTGTGTGCATCACA 
Db1 R2    CATTCTGGATCTAAACACATCTAGGCTTGC 
Vb10 SJ   CTCAGTGAGACTCATCGGTGC 
Db1.1 SJ  CATTAGCTCGCATCTTACCAC 
VhE          GTGGAGTCTGGGGGAGGCTTA 
Vh7183    CCAAGAAGACCCTGTACCTGCAAATGA 
Jhintronic CTCCACCAGACCTCTCTAGACAGC  
Jh4           TCAAATGAGCCTTCCAAAGTCC 
Spectral karyotyping (SKY) 
For metaphase preparations, primary tumor cells were grown in RPMI 
supplemented with 20% fetal bovine serum, L-Glutamine and beta 
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mercaptoethanol for 2 h and exposed to colcemid (0.025 μg/ml) and BrdU (28 
ug/ml) for an additional 2 hours at 37 °C. Then, cells were incubated in 40 mM KCl 
for 25 min at 37 °C, fixed in fixative solution (75% methanol/25% acetic acid) and 
washed twice in the fixative. Cell suspensions were dropped onto pre-chilled 
glass slides and air-dried. Spectral karyotyping was performed using the Applied 
Spectral Imaging mouse SKY probe according to the manufacturerʼs instructions 
to determine chromosomal rearrangements. The slides were analysed using a 
Nikon Eclipse 80i microscope. SKY images were captured and karyotyped using 
an Applied Spectral Imaging system. 
Adjacent Direct Repeat (ADR) Quantification 
ADRs were scored in a fashion such that repeats, which were generated 
randomly, were removed. First we calculated the insertion probabilities of 
A,T,G,C nucleotides. For that purpose, we omitted any insertions that could have 
been generated as P nucleotides and calculated nucleotides probabilities for 
each TCR beta locus separately. Second, we calculated the probability of a 
certain ADR to arise by multiplying the relevant nucleotide probability times the 
number of total junctions (For example: P(T)*P(A)*P(A)*N) for each locus. Any 
multiplication above 1 meant that, by chance, there is a likelihood of 1 junction to 
have a certain ADR. Therefore, to be stringent, we scored as statistically 
significant multiplication less than 0.5.  
 
	  
	  
27	  
Whole genome sequencing 
Detailed procedures can be found in ref 113. Genomic DNA from 
Rag2FS/FS;p53−/− tumor and liver (control) tissues was purified. Paired-end 
libraries were generated according to manufacturerʼs recommendations. Libraries 
were then analyzed for size distribution and sequenced on an Illumina HiSeq 
2000. Sequence coverage was calculated by (# Reads adjusted to duplication * 
average insert size in bp)/bp in the mouse genome). We obtained 35 and 37 fold 
coverage for tumor and liver respectively. Filtering pipeline is described in ref 30. 
Potential genomic candidates were validated by PCR using custom designed 
primers against tail DNA. Lesions that were validated as tumor specific were 
cloned (TOPO TA) and Sanger sequenced.  
Cryptic RSS (cRSS) Definition: To score for aberrant rearrangements involving 
cRSSs we used criteria that were generated in our lab (Mijuskovic M, in 
preparation). Basically, we identified the first ʻCAC/GTGʼ from the break point and 
reconstructed both a 12/23 RSS. V(D)J recombination requires synapsis of 12/23 
RSSs. Hence, we assessed our sequences from both sides of the break point in 
pairs. For example, if only one side of the break showed good identity to a 
consensus RSS we did not score this rearrangement as cRSS mediated. In 
addition we did not consider ʻCACʼ that where further than ~25bp from the break 
point.  
 
 
	  
	  
28	  
V(D)J recombination assay 
The 293T cell line was grown in DMEM supplemented with fetal bovine serum 
(10%), non-essential amino acids and penicillin-streptomycin. Cells were grown 
at 37 °C in the presence of 5% CO2. To assess V(D)J recombination, 0.5 μg of 
the indicated murine Rag1, murine Rag2 and recombination substrate were 
transfected into cells using a FuGENE 6:DNA ratio of 3:1. Forty-eight hours after 
transfection cells were harvested and fluorescent intensity was measured using 
BD LSR II for FACS readout. 
Spectratyping 
Immunoglobulin heavy chain repertoire analysis was performed using CDR3 
spectratyping. Briefly, genomic DNA from splenocytes was purified using 
PureGene and amplified using the J606.1 and the J558.85 VH primers and a 
fluorescent labeled JH2 reverse primer. 2 μL of PCR product per reaction were 
resolved by capillary electrophoresis on an ABI 3100 analyzer (Applied 
Biosciences Inc). Peak scanner v. 1.0 was used to generate and analyze the 
spectratypes (Applied Biosciences Inc).  
Statistical Analysis 
A two-tailed unpaired t-test was applied for extrachromosomal recombination 
efficiency and thymus cellularity. For all other statistical analysis we used the Chi-
Square test of independence. 
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RESULTS 
 
Signal joints from RAG2FS/FS mice show reported features of a-NHEJ 
To explore pathway choice control at the chromosomal level in repair-proficient 
animals we generated FS361RAG2 knock-in mice (Fig. 2.1B-D). We chose this 
mutant because it yields the highest levels of a-NHEJ of any RAG mutant tested 
in vitro (Fig. 2.1A and 36,74). Specifically, this allele yields 2.5 to 5 fold higher 
levels of a-NHEJ than "core" RAG2 (truncated at amino acid 383; 114,115) 
(Fig.2.1A, 36). RAG2FS/FS knockin mice exhibit a mild block in early lymphocyte 
differentiation (Fig.2.2) closely resembling that described for core RAG2 mice 
(RAG2C/C), and, as expected, remain capable of generating mature lymphocytes 
(112,116). 
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Figure	  2.1	  Generation	  of	  RAG2FS/FS	  knock-­‐in	  mice.	  	  A.	  RAG2FS	  has	  the	  highest	  a-­‐NHEJ	  
activity	  in-­‐vitro.	  293T	  cells	  were	  transiently	  transfected	  with	  full	  length	  Rag1,	  the	  
different	  Rag2	  mutants	  and	  the	  indicated	  substrate.	  Recombination	  was	  measured	  48h	  
post	  transfection	  by	  FACS	  analysis.	  Calculations	  are	  fold	  increase	  over	  full	  length	  Rag2	  
(RAG2).	  A.	  Recombination	  with	  RSSs	  in	  deletion	  configuration;	  RAG2,	  RAG2Core	  (a.a1-­‐
383)	  RAG2FS	  -­‐	  Frame-­‐shift	  mutation	  at	  amino	  acid	  361,	  DDE-­‐	  inactive	  Rag1.	  Absolute	  
recombination	  for	  RAG2	  28%±12.	  	  B.	  Recombination	  with	  a-­‐NHEJ	  substrate	  (15).	  *	  
p<0.0001	  vs	  RAG2,	  **p<0.001	  vs	  RAG2Core.	  RAG2	  absolute	  recombination	  is	  0.5%±0.25.	  
B.	  Mice	  were	  generated	  in	  inGenious	  Targeting	  Laboratory	  Inc.	  A~11.5kb	  region	  used	  to	  
generate	  the	  targeting	  vector	  was	  first	  sub	  cloned	  from	  a	  positively	  identified	  C57/Bl6	  
BAC	  clone.	  Two	  types	  of	  mutations	  were	  generated	  in	  exon	  3	  utilizing	  overlap	  extension	  
PCR.	  The	  first	  mutation	  comprised	  deletion	  of	  base	  1082	  (T)	  to	  generate	  a	  frameshift.	  
The	  second	  mutation	  is	  located	  67bp	  3’	  of	  the	  T	  deletion	  and	  comprised	  replacement	  of	  
the	  last	  435bp	  of	  coding	  sequence	  with	  the	  sequence-­‐	  AAGCGGCCGCGACTCTAG	  
followed	  by	  the	  3’	  UTR	  sequence.	  First,	  primers	  located	  5’	  and	  3’	  to	  two	  unique	  Kpn1	  (K)	  
sites	  that	  flank	  the	  location	  of	  the	  mutations	  were	  used	  to	  amplify	  a	  1.6kb	  fragment.	  
The	  mutations	  were	  introduced	  into	  this	  fragment,	  which	  was	  then	  reintroduced	  back	  
into	  the	  construct	  via	  ligation	  into	  the	  Kpn1	  sites,	  thus	  replacing	  the	  wild-­‐type	  Kpn1	  
fragment	  with	  the	  mutated	  Kpn1	  fragment.	  The	  Neo	  cassette	  is	  inserted	  228bps	  5	  to	  the	  
ATG	  in	  exon	  3	  using	  Red/ET	  recombineering	  technology	  with	  a	  short	  homology	  arm	  that	  
extends	  ~1.5kb	  5’	  to	  the	  Neo	  cassette.	  The	  total	  size	  of	  the	  targeting	  construct	  (including	  
the	  backbone	  vector)	  is	  15.3kb.	  C.	  Identified	  F1	  heterozygous	  mice	  were	  crossed	  with	  
Ella-­‐Cre	  transgenic	  mice	  to	  delete	  the	  floxed	  Neo	  cassette	  in	  vivo.	  An	  additional	  cross	  
between	  the	  +/F	  mice	  and	  wild-­‐type	  mice	  eliminated	  the	  transgene.	  Subsequent	  mating	  
of	  Cre-­‐F2	  (RAG2+/FS)	  generated	  littermates	  with	  the	  wild-­‐type	  (+/+),	  heterozygous	  
(RAG2+/FS)	  and	  homozygous	  (RAG2FS/FS)	  genotypes	  for	  analysis.	  Genotyping	  analysis	  was	  
done	  using	  the	  SQ1-­‐GGAGACTCCTGACTGGACCCTCAG	  and	  DL1-­‐
GATTCAGAGAGCAATATACCT	  primers.	  D.	  Sequence	  analysis	  of	  tail	  and	  liver	  DNA	  showed	  
an	  additional	  amino	  acid	  change	  at	  T296M	  that	  occurred	  during	  the	  targeting.	  
Nevertheless,	  this	  change	  did	  not	  affect	  the	  FS	  mutant	  functionality	  in	  our	  cell	  system	  
assay	  allowing	  us	  to	  still	  use	  it	  as	  a	  mouse	  model	  to	  investigate	  our	  questions.	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Figure	  2.2	  	  T	  and	  B	  cell	  development	  in	  RAG2FS/FS	  knock-­‐in	  mice.	  A.	  Thymocytes	  from	  
mice	  of	  the	  indicated	  genotype	  were	  stained	  with	  antiCD8-­‐PE-­‐CY7,	  antiCD4-­‐APC-­‐CY7,	  
antiCD25-­‐APC	  and	  antiCD44-­‐PE.	  B.	  Summary	  table	  of	  the	  different	  B	  and	  T	  cell	  
populations	  from	  6-­‐8	  week	  old	  mice	  n=7.	  RAG	  KO	  (RAG-­‐/-­‐)	  are	  combined	  analysis	  of	  Rag1	  
and	  Rag2	  KO	  n=4.	  B220+	  cells	  in	  the	  BM	  are	  gated	  on	  IgM-­‐.	  *p<0.05	  vs	  wild-­‐type.	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Initially we examined signal joints, which are informative for two reasons. First, 
the sequence of these junctions is noncoding, and thus not subjected to selective 
pressures during lymphocyte differentiation. Second, signal joints have a well-
defined structure, being formed by blunt ligation of the signal ends. In a signal 
joint the two RSSs abut and although the occasional insertion of nucleotides is 
seen, deletions in either RSS is rare. Hence, nucleotide sequence features 
considered characteristic of a-NHEJ (excessive deletions, long insertions, and 
junctional microhomologies) are readily identified. 
Signal joints arising from recombination at the T cell receptor (TCR) beta locus in 
RAG2FS/FS mice exhibited a significant increase in imprecise joints (63/140, 45%) 
compared with age-matched wild-type controls (34/159, 21.4%) (p<0.0001, Table 
1). RAG2FS/FS junction sequences showed a significant increase in deletions 
(32/63, 50.7%, vs 6/34, 17.6%, seen in junctions from wild-type mice, p<0.001; 
Table 1). Strikingly, at least 50% of deleted signal ends from RAG2FS/FS mice had 
deletions greater than 5 nucleotides, a feature not observed in over 150 signal 
joints from wild-type mice (Table 1, Fig.S1). Other sequence features considered 
characteristic of a-NHEJ not observed in junctions from wild-type mice included 
occasional microhomologies (5/140 junctions, ranging from 2-9bp), and large 
insertions (350bp and 26bp; Fig.S1). A similar trend was previously observed in 
mice bearing the less severely truncated core RAG2 allele (110) and also the 
RAG2 T490A allele (in which the protein degradation signal is ablated; 28) 
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signifying the importance of an intact RAG2 C terminus. In aggregate, these 
features indicate that signal ends are abnormally available to a-NHEJ in 
RAG2FS/FS mice, suggesting that repair pathway choice is disabled.
 
Table	  1.	  RAG2FS/FS	  mice	  exhibit	  a-­‐NHEJ	  at	  the	  signal	  joints.	  Sequences	  analyses	  from	  2-­‐3	  
independent	  mice	  were	  combined.	  Frequencies	  of	  N	  nt	  additions,	  deletions,	  
miscleavage	  and	  microhomology	  were	  calculated	  out	  of	  imprecise	  junctions.	  
Deletions>5bp	  is	  calculated	  out	  of	  total	  deleted	  ends	  (5bp	  deletion	  was	  the	  longest	  seen	  
in	  wild-­‐type	  and	  thus	  chosen	  as	  a	  cutoff).	  Miscleavage	  represnts	  coding	  end	  sequences	  
at	  the	  ends,	  §	  p<0.01	  vs	  wild-­‐type;	  *	  one	  insertion	  was	  350bp	  from	  Vb3	  region	  (Fig.	  S1);	  
**	  2	  junctions	  underwent	  open-­‐shut	  intermediate	  (indicated	  in	  blue,	  Fig.S1). 
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Coding joints from RAG2FS/FS mice fail to exhibit reported features of a-
NHEJ 
We next examined coding joints formed at immunoglobulin (Ig) and TCR loci. 
Unlike signal joints, nucleotide sequences of coding joints from the two models 
(RAG2FS/FS, n=136; wild-type, n=94) were qualitatively similar (Table 2, Fig.S2). 
Because of the potential for bias imposed by biological selection for productive 
rearrangements (101), we also analyzed coding joints from (non-coding) D-J 
rearrangements and from sorted CD4/CD8 double negative thymocytes (which 
are not subject to selection for productive rearrangements; Table 2) Again, there 
was no qualitative difference between RAG2FS/FS and wild-type mice. Finally, we 
looked at the third complementarity-determining region (CDR3) sequence of 
antibody heavy chain gene rearrangements in genomic DNA of splenocytes from 
wild-type and RAG2FS/FS mice. The CDR3 is generated by V(D)J rearrangement 
and is influenced by non-templated additions and deletions. Significant shifts in 
CDR3 length, therefore, can serve as indirect evidence of a-NHEJ repair. CDR3 
spectratyping of VH606 and VH558 rearrangements to JH2 from splenocytes 
revealed no significant differences (Fig.S2F).  
We considered three reasons for the lack of distinctive sequence features at 
coding joints formed in RAG2FS/FS mice. One, the RAG2 FS allele might 
selectively enforce pathway choice for signal ends, but not for coding ends. Two, 
competition from c-NHEJ could render the "background" of normal coding joints 
too high to allow us to detect rare joints formed by a-NHEJ. Three, coding joints 
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formed by a-NHEJ may not be structurally distinctive. To explore these 
possibilities further, we used more sensitive assays to detect coding joints formed 
by a-NHEJ. 
   
Table	  2.	  No	  detectable	  a-­‐NHEJ	  repair	  at	  antigen	  receptor	  coding	  joints	  in	  RAG2FS/FS	  
mice.	  Sequence	  data	  from	  2-­‐3	  independent	  thymic	  or	  BM	  genomic	  DNA	  samples	  were	  
combined.	  The	  frequency	  of	  deleted	  ends	  at	  the	  V	  or	  J	  regions	  was	  from	  total	  events.	  
Average	  of	  base	  pair	  (bp)	  deletion	  and	  frequency	  of	  >4bp	  deletion	  was	  calculated	  out	  of	  
deleted	  events	  only	  (4bp	  was	  the	  average	  deleted	  length	  in	  wild-­‐type	  junctions	  and	  thus	  
chosen	  as	  a	  cutoff).	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RAG2FS/FS mice show increased inter-chromosomal rearrangements 
between antigen receptors together with excessive deletions 
a-NHEJ has been firmly implicated in chromosome translocations in various end 
joining-deficient backgrounds, and the translocation junctions show characteristic 
sequence features such as microhomologies and excessive deletions (9,46,37). 
We therefore investigated our RAG2FS/FS mice for elevated levels of 
translocations. In particular, abnormal translocations between the TCRβ and 
TCRδ loci, located on chromosomes 6 and 14, respectively, has previously been 
observed in mice bearing another RAG2 mutation (99). The D regions involved 
are flanked by a 12 and a 23 RSS which can lead to signal joints or coding joints 
products in a translocation junction (Fig.2.3A). We detected translocations in 4 
out of 5 RAG2FS/FS mice, but not in thymocytes from wild-type controls (n=4, 
p<0.02). We observed excessive deletions in 6/10 junctions with evidence in one 
case for a 2 bp junctional microhomology (Fig.2.2B). Unexpectedly, none of the 
junctions retained the D region coding end sequences. Because of this we could 
not establish whether the extensively deleted translocation junctions were 
abnormal coding joints or signal joints. Nonetheless, the observation of 
chromosomal translocations suggests that pathway choice is defective in the 
RAG2 mutant mice, in agreement with our analysis of signal joints. 
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Figure	  2.3	  RAG2FS/FS	  interchromosomal	  rearrangements	  within	  the	  antigen	  receptor	  
loci.	  	  
A.	  Scheme	  of	  the	  germ-­‐line	  configuration	  of	  TCR	  beta	  and	  delta	  and	  the	  predicted	  
products	  upon	  interchromosomal	  rearrangements.	  Rectangles	  represent	  coding	  gene	  
segments;	  triangles	  represent	  RSS	  (Filled	  -­‐12RSS,	  open	  -­‐	  23	  RSS).	  The	  arrows	  indicate	  
nested	  PCR	  primers.	  B.	  Sequence	  analysis	  of	  purified	  PCR	  products	  (n=4	  RAG2FS/FS	  mice).	  
Capital	  letters	  at	  the	  middle	  of	  the	  junction	  represents	  N	  nt,	  Bold	  italic	  are	  
microhomology,	  deletions	  are	  indicated	  in	  parentheses	  and	  small	  letters	  are	  Sanger	  
sequence	  that	  did	  not	  align	  to	  mouse	  mm9	  database.	  
 
 
Coding joint formation bypasses Ku80 deficiency in RAG2FS/FS mice 
Ku80-/- mice lack a critical component of c-NHEJ, and are thus severely deficient 
for both coding and signal joints, leading to a complete block in lymphocyte 
differentiation at the proB/proT stage (108). We reasoned that if pathway choice 
were no longer imposed by C-terminally truncated RAG2, the joining of V(D)J 
recombination intermediates, no longer restricted to c-NHEJ only, might become 
possible. In other words, lack of joining in Ku80-null animals might be rescued by 
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an alternative pathway in Ku80/RAG2FS double mutants. Furthermore, 
nucleotide sequence analysis of the V(D)J junctions formed in these mice (in the 
absence of c-NHEJ) should help interpreting the coding joints formed in 
RAG2FS/FS mice. 
 
RAG2FS/FS;Ku80-/- double mutants demonstrated a significant (~ 4 fold, p<0.05) 
increase in thymus cellularity compared with Ku80-/- mice, suggesting a partial 
bypass of the developmental block (Fig.2.4A). FACS analysis showed that T cells 
progressed into the CD4/CD8 double positive (DP) stage in over half of the 
animals (10/17 p<0.05, Fig.2.4B-C). As expected, Ku80-/- mice lacked CD4/CD8 
positive cells except for one mouse that had a very small DP population 
(Fig.2.4C, 108). Because developmental progression is linked to successful 
V(D)J recombination, these indications invited further examination of the 
possibility that the RAG2FS allele rescued TCR beta rearrangement.  
 
We detected cell surface TCR beta expression in one double mutant mouse 
(Fig.2.4B), and demonstrated V(D)J joining via PCR analyses in several other 
RAG2FS/FS;Ku80-/-animals. We detected no TCR rearrangements in Ku80-/- mice, 
in accordance with previous work (108). In the double mutants we observed TCR 
beta and alpha rearrangements  (Vβ14, Vβ10, and Vα8) (Fig.2.5). DNA 
sequence analysis revealed complete (V to D to J) and diverse coding joints. The 
FS allele can, therefore, substantially rescue joining of coding ends and bypass 
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the joining defect that is otherwise observed when Ku80 is not present. The joints 
we observed were formed in the absence of c-NHEJ, and are therefore 
generated, by definition, by a-NHEJ. We conclude that the C-terminal RAG2 
truncation ablates pathway choice control, allowing coding ends to be joined via 
a-NHEJ. 
 
 
Figure	  2.4	  RAG2FS/FS	  mutant	  can	  by-­‐pass	  Ku80	  deficiency.	  Mice	  from	  the	  indicated	  
genotypes	  were	  sacrified	  at	  4	  weeks	  for	  analysis.	  A.	  Thymus	  cellularity	  by	  trypan	  blue.	  p	  
vs	  Ku80-­‐/-­‐	  B.	  Thymocytes	  were	  stained	  with	  antiThy1.2+FITC,	  antiCD4-­‐APC,	  antiCD8-­‐
AF700	  and	  antiTCR	  beta-­‐PE.	  Double	  positive	  (DP)	  populations	  and	  TCR	  beta	  were	  
calculated	  by	  gating	  on	  Thy1.2+	  cells.	  C.	  Distribution	  of	  DP	  cells;	  only	  DP	  >1%	  was	  
considered	  as	  positive.	  Number	  of	  mice	  analyzed	  is	  indicated.	  *p	  <0.05	  vs	  Ku80-­‐/-­‐	  
 
	  
	  
41	  
	  
Figure	  2.5 Sequence	  analysis	  of	  TCR	  beta	  and	  alpha	  junctions	  from	  RAG2FS/FS	  Ku80-­‐/-­‐	  
mice.	  Genomic	  DNA	  was	  prepared	  from	  RAG2FS/FS;Ku80-­‐/-­‐	  thymocytes	  (n=2-­‐4).	  TCR	  Vβ14-­‐
Jβ1.1,	  TCR	  Vβ10-­‐Jβ2.1	  and	  TCR	  Vα8-­‐Jα58.	  Germline	  sequences	  are	  indicated	  at	  the	  top.	  
Capital	  letters	  in	  the	  middle	  of	  the	  junction	  indicate	  N	  nt,	  capital	  bold	  -­‐	  P	  nt,	  deletions	  
are	  in	  parentheses	  and	  blue/red	  represents	  the	  Adjacent	  Direct	  Repeats	  (ADRs).	  	  +/-­‐	  
indicates	  in/out	  of	  frame	  rearrangements	  respectively.	  	  
	  
 
	  
	  
42	  
Unusual characteristics of coding joints in RAG2FS/Ku80 double mutants 
The rescued, Ku80-independent, coding joints lacked features of a-NHEJ that 
have been reported in other systems (49,117). As in the RAG2FS/FS mice, we saw 
neither a dependence upon microhomology nor unusually large deletions 
(Fig.2.5). These data suggest that, in the context of coding joint formation, a-
NHEJ does not display attributes commonly observed in other systems. We did, 
however, observe an unusual feature:  short, 3-5 nucleotide repeats were evident 
in many of the junctions formed at the Vβ14 locus (Fig.2.5) in double mutant 
mice. By a conservative analysis designed to minimize counting repeats 
generated by chance (see Methods), 5/22 (23%) Vβ14 junctions contained 
“Adjacent Direct Repeats” (ADRs). The sequence features of ADRs (being in 
direct orientation and immediately adjacent) imply a mechanism in which 
processed ends with complementary extensions (acquired through addition of P 
or N nucleotides) are annealed and then displaced by a gap-filling polymerase 
before ligation (Fig.2.6A). Efficient strand displacement is not a known 
characteristic of either polλ or polμ (118,119) which, along with TdT, are the 
polymerases thought to be associated with c-NHEJ (8). Pol β, another member of 
the polX polymerase family, has gap-filling and strong strand-displacement 
properties (118) and while active in base excision repair (120), has not been 
described as a factor in c-NHEJ.  
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Figure	  2.6	  Generation	  of	  Adjacent	  Direct	  Repeats	  -­‐ADRs	  
A.	  Scheme	  showing	  how	  small	  ADRs	  (adjacent	  direct	  repeats)	  might	  be	  generated.	  The	  
first	  step	  may	  or	  may	  not	  be	  a	  mechanistic	  constraint	  however	  it	  is	  necessary	  in	  the	  
identification	  of	  ADRs.	  We	  show	  homologies	  between	  ends	  having	  been	  generated	  by	  
TdT	  or	  perhaps	  another	  polymerase	  (121).	  Terminal	  homologies	  can	  also	  be	  revealed	  
between	  two	  ends	  by	  resection	  but	  were	  excluded	  in	  our	  analysis	  because	  prior	  existing	  
sequences	  between	  ends	  that	  can	  generate	  ADRs	  are	  indistinguishable	  from	  simple	  
direct	  joining	  products	  and	  difficult	  to	  score.	  The	  next	  step	  is	  stabilizing	  end-­‐to-­‐end	  
interaction	  via	  complementary	  bases	  in	  the	  two	  single	  strand	  extensions	  compensating	  
for	  the	  lack	  of	  Ku80.	  We	  suggest	  that	  annealing	  occurs	  near	  or	  at	  the	  termini.	  For	  the	  
sake	  of	  parsimony,	  we	  have	  depicted	  Fen-­‐1	  as	  the	  flap	  removal	  factor	  prior	  to	  the	  gap-­‐
filling	  and	  strand	  displacement	  steps.	  ADRs	  are	  then	  generated	  when	  a	  gap-­‐filling	  
polymerase	  with	  strand	  displacement	  activity	  is	  present.	  This	  could	  be	  supplied	  by	  pol	  
lamda	  (119),	  which	  has	  sufficient	  strand	  displacement	  activity	  in	  vitro	  with	  the	  
cooperation	  of	  Fen-­‐1,	  to	  invade	  three	  or	  four	  bp	  into	  a	  duplex,	  or	  by	  pol	  beta,	  which	  
display	  stronger	  strand	  displacement	  on	  its	  own	  (118).	  The	  latter	  is	  not	  a	  known	  
participant	  in	  c-­‐NHEJ,	  but	  is	  also	  stimulated	  by	  Fen-­‐1	  in	  vitro	  (119).	  Following	  
polymerization/strand	  displacement	  of	  one	  end	  the	  second	  detached	  end	  could	  be	  
either	  filled	  in	  by	  ‘conventional’	  extension	  and	  then	  ligated	  or	  alternatively,	  ligated	  and	  
then	  filled	  in.	  
B.	  Summary	  of	  the	  number	  of	  junctions	  with	  ADRs	  detected	  in	  our	  study	  and	  by	  re-­‐
examination	  of	  published	  data	  (28,110).	  The	  ADRs	  are	  indicated	  in	  Blue-­‐Red	  in	  Fig	  S2.	  nd	  
stands	  for	  Not	  Done.	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The high prevalence of ADRs at the Vβ14 locus prompted us to re-examine 
coding joints from this locus in wild-type RAG2 and RAG2FS/FS mice. We found 
that 1/11 TCR rearrangements from wild-type RAG2 and 1/14 from RAGFS/FS 
mice exhibit this feature (Fig.S2C). We also detected similar levels of ADRs upon 
review of published coding joint sequences at Vβ14 collected from wild-type mice 
(3/47 and 3/40; refs 28 and 110, respectively, Fig.2.6B). Although initially 
observed at Vβ14, ADRs can also be detected elsewhere (Vβ10, Vβ6-8, Dβ2; 
Fig.2.6B). The frequency of ADRs is increased in the absence of Ku80, implying 
an association with a-NHEJ. However, like other reported a-NHEJ sequence 
features (35), they are also observed in junctions from c-NHEJ-proficient animals.  
 
Together, these data allow us to draw the following conclusions. Ends that are 
formed in the absence of RAG2ʼs C-terminus in c-NHEJ-proficient mice are 
accessible to a-NHEJ, as shown by signal joints bearing features characteristic of 
a-NHEJ, and also by the coding joints that are rescued in Ku80-deficient mice. 
Thus, the C-terminus of RAG2 is important for restricting the end-joining 
pathways that can repair RAG-generated DSBs in vivo. Additionally, our results 
suggest that Ku80-independent repair is not a disordered, unregulated alternative 
to c-NHEJ, because rescued coding joints exhibit uniform structural features, 
resembling junctions formed in RAG2 wild-type and RAG2FS/FS mice.  
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A more extensive RAG2 C-terminal truncation also generates aberrant 
V(D)J joints and rescues coding joint formation in Ku80-deficient mice  
In the FS allele, the normal RAG2 sequence truncates at amino acid 361, but is 
followed by a novel stretch of 28 amino acids at its C terminus before the protein 
sequence terminates at a fortuitous stop codon (36). Through whole genome 
sequencing, we discovered that the core RAG2 allele in the RAG2C/C mice 
(derived in the laboratory of M. Schlissel) is not as reported (112) and is a more 
extensive truncation that terminates at amino acid 352 (instead of the reported 
383), with 5 extra C-terminal amino acids encoded by the targeting vector 
(Fig.2.7A). We used mice homozygous for this allele, which we rename 
RAG2del352, to verify the results obtained with the FS allele.   
 
We analyzed signal joints and interchromosomal rearrangements from 
homozygous RAG2del352/del352 mice and TCR rearrangements from 
RAG2del352/del352;Ku80-/- homozygotes and found results similar to those obtained 
with RAG2 FS allele (Fig.2.7B-D). These data extend the results obtained with 
RAG2FS/FS mice, indicating that the phenotype is not an artifact of the C-terminal 
extension encoded by the FS allele, and underscore the importance of the RAG2 
C terminus in repair pathway choice in vivo. 
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Figure	  2.7	  RAG2del352	  mice	  junctions’	  analysis.	  	  A.	  Diagram	  of	  the	  RAG2del352	  allele.	  A	  
change	  in	  RAG2	  sequence	  after	  amino	  acid	  352	  originating	  from	  the	  targeting	  vector	  is	  
indicated	  in	  red.	  B.	  Signal	  joint	  analysis	  from	  different	  TCR	  loci	  n=2-­‐6.	  (Analysis	  was	  
preformed	  as	  specified	  in	  Table	  1).	  C.	  Dδ2-­‐Dβ1	  interchromosomal	  rearrangements	  from	  
healthy	  thymocytes	  n=3	  D.	  RAG2del352/del352;Ku80-­‐/-­‐	  antigen	  receptor	  rearrangements	  
from	  the	  indicated	  loci	  n=1-­‐3.	  (Annotations	  are	  as	  given	  in	  Fig.2.5).	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a-NHEJ in aberrant genomic rearrangements from a RAG2FS/FS;p53-/- 
lymphoma 
Several laboratories have reported a connection between a-NHEJ, chromosomal 
translocations, and accelerated lymphomagenesis (9,10,46,37). Indeed, c-NHEJ 
knock-out mice crossed to a p53-deficient background develop lymphomas with 
chromosome translocations mediated by a-NHEJ (9,10). To test the possibility 
that structural features reported for a-NHEJ might exist in genomic lesions from 
lymphomas, we generated RAG2FS/FS;p53-/- mice. Thymic lymphomas emerged 
rapidly, with median survival of 13.5 weeks (vs. 22.5 weeks in p53-/- mice) 
(p<0.002, Fig.2.8A). Tumor cells expressed surface CD4 and CD8 with variable 
amounts of surface TCR beta, implying that these lymphomas originated from 
immature thymocytes (Fig.2.8B). Spectral karyotyping (SKY) analysis of these 
thymomas showed a wide spectrum of chromosome translocations, including but 
not limited to chromosomes bearing antigen receptor loci (Fig.2.8C).  
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Figure	  2.8	  RAG2FS/FS;P53-­‐/-­‐	  mice	  develop	  rapid	  lymphoma	  with	  genomic	  instability.	  	  
A.	  Kaplan-­‐Meier	  survival	  curve	  of	  the	  indicated	  genotyped.	  p	  vs	  P53-­‐/-­‐	  mice.	  B.	  FACS	  
analysis	  of	  representative	  wild-­‐type	  thymus	  and	  RAG2FS/FS;p53-­‐/-­‐	  thymic	  lymphomas.	  C.	  .	  
SKY	  analysis	  of	  RAG2FS/FS;P53-­‐/-­‐	  T	  cell	  lymphomas.	  *	  indicates	  antigen	  receptor	  
chromosome	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To determine whether sequence features of a-NHEJ might be apparent in 
genomic lesions, we employed our previously established analysis pipeline to 
detect structural variants (translocations, deletions, inversions, and duplications) 
in paired-end whole genome sequence data (113). We analyzed two 
RAG2FS/FS;P53-/- tumors and identified 47 genomic rearrangements including 
translocations and intra-chromosomal rearrangements (deletions, inversions and 
duplications, Table 3). 14 rearrangements were the result of normal antigen 
receptor junctions. The remaining 33 rearrangements were aberrant junctions: 20 
deletions, 9 inversions, 2 duplications and 2 translocations. Both of the detected 
translocations were between chromosome pairs previously identified as having 
undergone an exchange by SKY analysis of this same tumor (Fig.2.8C) 
16 aberrant junctions showed features associated with a-NHEJ, mainly 
microhomologies. (Fig.2.9). One junction had both a 3bp microhomology and a 
large insertion (103bp) comprised of a duplicated sequence centromeric to the 
break point and 5 non-templated nucleotides, a structure highly suggestive of a-
NHEJ. The rest of junctions had microhonology between 1-5bp with a majority of 
1-2bp. Interestingly, most of the inversion junctions exhibited microhomology 
suggesting that the complexity of the repair (joining four ends vs two ends) might 
effect end joining. A third feature associated with a-NHEJ, excessive deletion, 
can be measured only if an initial break site is known, which is rarely the case for 
random rearrangement. However, the immature T cell phenotype of these tumors 
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(Fig.2.8B), together with evidence of V(D)J recombination in our example 
suggested it might be worthwhile to examine junctions for evidence of having 
been RAG-generated. In such cases, we could assume cleavage at sequences 
fortuitously resembling RSSs (cryptic RSS, or cRSS), and take advantage of this 
to score deletion. Indeed, we were able to identify 10 junctions associated with 
credible cRSS bearing identifiable heptamer and nonamer sequences at both 
ends (Table 3). Two of the junctions exhibited a typical limited amount of deletion 
from the cRSSs, but one exhibited more extreme deletion from each breakpoint 
(15bp on one side, and 16bp on the other), consistent with a-NHEJ. This junction 
was created by a translocation. In summary, if we assume that c-NHEJ cannot 
tolerate microhomology to any degree, half of the aberrant rearrangements in the 
tumors exhibited characteristics reported for a-NHEJ. However, the remaining 
junctions cannot be unequivocally assigned to either a-NHEJ or c-NHEJ because 
our findings show that a-NHEJ junctions are not necessarily distinct from those 
formed by c-NHEJ.  
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Table	  3.	  Structural	  variants	  from	  RAG2fFS/FS;p53-­‐/-­‐	  tumors.	  SVs	  from	  WGS	  of	  two	  tumors	  
(13422,	  12333)	  were	  grouped	  into	  4	  categories:	  ‘RSS-­‐RSS’	  in	  gray	  are	  antigen	  receptor	  
rearrangements	  using	  bona	  fide	  RSSs.	  ‘RSS-­‐	  cRSS’	  in	  yellow	  are	  rearrangements	  that	  only	  
one	  side	  had	  a	  bona	  fide	  RSS	  with	  the	  other	  being	  cRSS.	  ‘cRSS-­‐cRSS’	  in	  blue	  are	  
rearrangements	  outside	  of	  the	  antigen	  receptor	  loci	  potentially	  mediated	  via	  cRSSs.	  
‘Other’	  represents	  all	  the	  rest	  of	  the	  genomic	  lesions	  that	  could	  not	  be	  assigned	  to	  any	  
of	  the	  other	  groups.	  The	  name	  of	  the	  SV	  is	  #tumor-­‐#ch-­‐variant	  #	  (type	  of	  lesion;	  
DEL=deletion,	  INV=	  inversion,	  Dup=duplication,	  Tx=translocation).	  Red	  indicates	  
nucleotides	  similarity	  to	  consensus	  heptamer	  and	  nonamer.	  In	  ‘insert’	  column,	  bold	  
letters	  are	  P	  nucleotides.	  IGR	  stands	  for	  intergenic	  region.	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Figure	  2.9	  Junctional	  sequence	  of	  the	  SVs.	  	  All	  identified	  Svs	  are	  presented	  here.	  In	  blue	  
and	  green	  are	  the	  germ	  line	  sequences	  of	  each	  breakpoint	  (upper	  and	  lower	  row,	  
respectively).	  Middle	  line	  represents	  the	  junction	  itself.	  Bold	  black	  are	  insertion	  and	  bold	  
black	  italic	  are	  microhomologies.	  The	  numbering	  correlates	  to	  those	  in	  table	  3.	  A.	  
endogenous	  V(D)J	  rearrangements.	  B.	  bona	  fide	  RSS	  to	  cRSS	  and	  cRSS	  to	  cRSS.	  C.	  all	  
other	  SVs	  that	  could	  not	  be	  assigned	  to	  any	  of	  the	  other	  groups.	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DISCUSSION 
 
We used two knockin mouse models, RAG2FS/FS and RAG2del352/del352, to 
demonstrate that in both c-NHEJ-proficient and c-NHEJ-deficient animals, 
removing RAG2's C-terminus allows aberrant use of a-NHEJ to join physiologic, 
chromosomal DSBs. These data provide the first evidence that pathway choice 
operates during normal V(D)J recombination in vivo. Is pathway choice 
physiologically relevant in c-NHEJ-proficient animals? Our data suggest that 
defects in pathway choice may explain, at least in part, the genomic instability 
seen in lymphomas from RAG2FS/FS;p53-/- mice. However, until a-NHEJ is better 
defined we cannot rule out involvement of c-NHEJ in such rearrangements.   
 
Additional evidence that RAG2's C-terminus is important for controlling repair 
pathway choice is provided by analysis of N nucleotide addition. Previous work 
showing that junctions formed in the absence of Ku80 were devoid of N additions 
indicated that Ku80 is important for recruiting terminal deoxynucleotidyl 
transferase (TdT) to DSBs (107,122,123). This does not appear to be the case in 
the presence of RAG2 C-terminal truncations where coding joints from double 
mutant mice displayed N regions. We speculate that this may be another feature 
of abrogated pathway choice control, in which TdT has unregulated access to 
RAG-mediated DSBs in the absence of RAG2's C-terminus. This is supported by 
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our observation that in RAG2FS/FS mice, N regions are significantly more prevalent 
at signal joints (35% in RAG2FS/FS mice vs 20% in wild-type p<0.006).  
 
Because RAG2 C-terminal mutants allow joining by a-NHEJ, characteristics of 
chromosomal a-NHEJ can be studied in both c-NHEJ-proficient and c-NHEJ-
deficient animals. Surprisingly, coding joints repaired by a-NHEJ do not exhibit 
features commonly associated with a-NHEJ, even in the absence of Ku80. The 
resemblance of a-NHEJ repair to that of c-NHEJ implies that the former might be 
more prevalent than appreciated and can, like c-NHEJ, repair physiological DSBs 
in a non-mutagenic fashion. This discovery suggests that we must exercise 
caution when interpreting features of DNA rearrangements in sequenced tumor 
genomes. Moreover, the unified sequence features of these junctions (e.g. the 
lack of a subset of junctions bearing excessive deletions, insertions or 
microhomologies) imply that they may be formed by a single repair pathway, 
rather than through a hodgepodge of joining activities. Our data have another 
important implication, which is that alternatives to c-NHEJ cannot be presumed to 
have an impact on junction structure. Only upon close scrutiny could we detect 
any difference between the Ku80-independent coding joints and those generated 
in wild-type mice (ADRs, discussed in results). Thus, either many repair factors 
are shared between c-NHEJ and alternative joining mechanisms, or the 
alternative pathway used to join coding ends is organized to call up a similar 
compilation of different enzymes that pretty nearly reconstruct the products of c-
	  
	  
60	  
NHEJ. We are not the first to question the existence of a single, well-defined 
alternative NHEJ pathway (35,8), however, this study contributes a definitive 
illustration of the lack of consistency between different systems. 
 
The striking finding that most coding joints have normal structures is in apparent 
conflict with both the signal joints recovered in this study as well as with results 
from our cell-based assay in which the RAG2FS mutant allows coding joints 
bearing excessive deletions and microhomologies to be formed on an 
extrachromosomal substrate (36). These apparent discrepancies may be the 
consequence of a context-dependent aspect of a-NHEJ. There are obvious 
differences in the requirements in each case: signal ends prior to joining have 
blunt-ended termini, coding ends need to undergo several processing steps 
before they can become ligated. There is evidence that the structure of the DNA 
ends at a DSB can affect their resolutions (124). An extrachromosomal substrate 
can reflect much about physiological joining, however, there can be a difference 
between end-joining where cut ends are closely linked and may be able to collide 
at random, versus ends in the chromosome, where a break must be somehow 
bridged and stabilized for joining. Lastly, the sequence environment surrounding 
the DSBs may also influence joining. In immunoglobulin class switch 
recombination, the almost invariant appearance of microhomology at junctions 
produced by a-NHEJ may be attributed to the repetitive nature of the switch 
regions (125,126). This might also be the case in our extrachromosomal 
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substrate, where a substantial (9 nt) microhomology is present near the break 
points (36). In antigen receptor loci, which lack this repetitive sequence 
environment, such repair might not be similarly favored.   
 
Whether the V(D)J joining system refines the outcome of joining by controlling 
where and when cleavage occurs (ie ʻcontextʼ) and by handing off the coding 
ends to defined pathways, and how this is achieved at a mechanistic level will be 
relevant to unraveling the mechanisms responsible for preserving genomic 
integrity during V(D)J recombination, and may illuminate end-joining metabolism 
in general. 
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CHAPTER 3 
The RAG2 C terminus protects against illegitimate V(D)J 
recombination 
 
The V(D)J recombination process is a double edged sword. On the one hand it is 
crucial for the development of the adaptive immune system and its diversity. On 
the other hand, it inadvertently causes genomic instability contributing to 
malignant transformations. This illegitimate V(D)J recombination process can be 
caused through a variety of mechanisms (Fig. 1.3). This chapter will deal with 
events that are mediated via cryptic RSSs (cRSSs, groups 2-4in Fig. 1.3) 
because they are recognized as major contributors to lymphoma neoplasms.  
Aberrant V(D)J recombination by the RAG complex can potentially occur every 
600-1000bp in the mouse or human genome respectively (96). Obviously not all 
cRSSs are the same and some are more effective than others, as reported in 
systematic functional analyses (127,128). These studies showed that there is 
more to an RSS than a heptamer or nonamer. The recombination efficiency of an 
RSS is a summation of all its regions, conserved or non-conserved. It is almost 
impossible to identify a functional cRSS based on sequence alone. A 
comprehensive cRSS predication algorithm failed to favorably score multiple 
cRSS that can undergo recombination in-vitro (96,129). 
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SKY analysis of tumors from RAG2FS/FS; p53 -/- mice showed a high percentage of 
translocations occurring mostly outside of antigen receptor chromosomes (66% 
of breaks, Fig.2.8C). As such translocations are not frequent in lymphomas from 
p53-/- mice, we hypothesized that the C terminus of RAG2 might inhibit cRSS 
usage to protect the genome integrity. If true, an increased usage of cRSS by the 
FS allele may provide an additional mechanism by which the lymphomas 
observed in RAG2FS/FS;p53-/- mice evolve. Indeed, our RAG2FS/FS;p53-/- tumor 
data revealed that 27% of the genomic lesions (excluding normal V(D)J 
rearrangements) were potentially mediated via aberrant V(D)J recombination 
with some involving genes implicated in oncogenesis and genome stability 
(Trmt2a (130), TNFR2 (131), CD30 (132), Notch1 (93), Zranb3 (133) and Plxna4 
(134)). 
Several other results were supportive of this theory. RAG2del352/del352 mice were 
shown to favor some RSSs more than others implying that the C terminus plays a 
role in RSS selection (112). Moreover, the FS allele lacks the plant homeodomian 
(PHD) of RAG2 (414-487 amino acid) that binds to trimethylated Histone 3 at 
lysine 4 (H3K4me3) (89,90). This region destabilizes the RAG-DNA complex 
impeding cleavage unless bound by H3K4me3 (135). RAG2FS/FS mice are 
deficient in this level of regulation and hence can cleave in sites irrespective of 
this epigenetic signal (135).  
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Functional recombination assays regarding the dynamic between the RAG 
complex and various cRSSs was only tested in the context of full length RAG2 
(FLR2). A consistent observation was that both heptamer and nonamer, with a 
certain degree of deviation from a consensus sequence, are obligatory for V(D)J 
activity (127,128). Different sequence changes in either region were tolerated to 
variable degrees (127). Additionally, biochemical studies using purified core 
RAG1/2 showed that the heptamer, specifically the ʻCACʼ, is critical for complete 
cleavage and hairpin generation while the nonamer is important for RSS binding 
and cannot promote cleavage without a heptamer present (129,136). 
Nonetheless, understanding of the exact mechanism/s of how illegitimate V(D)J 
recombination occurs is still lacking. 
 
Illegitimate V(D)J activity has not been functionally tested with different RAG 
mutants. In light of our tumor data we decided to address this issue. First, we 
wanted to test whether the FS allele indeed increases aberrant V(D)J activity in a 
more robust fashion. If these were to hold true, we then sought to examine if 
various modification to the RGA2 C terminus might be more sensitive to changes 
in the RSS sequence. 
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Methods 
Notch1 and Bcl11b intragenic deletions 
Genomic DNA from thymocytes was prepared using the Roche High Pure PCR 
template preparation kit according to manufacture recommendations. Nested 
PCR was preformed to detect intergenic deletion for both genes. PCR protocols 
and primers were described previously (93,94). Modified primers for Bcl11b are 
described below. For a negative control we used genomic DNA from R2 KO liver. 
PCR samples were analyzed by electrophoresis on agarose gels. Identification of 
a band at the appropriate size was considered an indication of rearrangement. 4 
samples from RAG2FS/FS mice and positive RAG2 wild-type were purified, TOPO 
TA cloned, and Sanger sequenced. 
Primers: 
Bcl11b F1 CTCTCCAATCCTGTGGTCTCTTAC 
Bcl11b F2 GGGAACGCTTTTCGGCCTTACTTG 
Bcl11b R1 GTCAGCCTAAGGCTACAGCACATTATG 
Bcl11b R2 CTCTTCTGCACAGCTTTCCCTCTG 
 
Extrachormosomal assay with human cRSS (LMO2/TAL2) 
We used an in vitro system in eukaryotic cells that measures recombination 
efficiency. The substrates were a gift from Dr. B Nadel and are described in detail 
in ref 137. Briefly, the substrates have the two sequences to be tested that are 
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separated by a termination signal (oop). Hence a chloramphenicol 
acetyltransferase (CAT) gene will only be transcribed in E. Coli upon successful 
recombination that deleted the opp sequence in cells. The substrate also carries  
ampicillin (AmpR) resistance that was used to calculate recombination 
efficiencies. RMP41 fibroblast were transfected with full length Rag1 and the 
different Rag2 mutants together with a recombination substrate as a read out. 48 
Hours post transfection we harvested the cells and obtained DNA by 
phenol/chloroform extraction. DpnI-digested plasmids were then introduced into 
chemically competent E. coli, and plated on ampicillin (100 μg/ml) and 
chloramphenicol (10 μg/ml). Absolute recombination efficiency was calculated by 
dividing the number of double resistant colonies by the total number of colonies 
(AmpR alone). As a control we transfected the substrate alone without Rag1/2 to 
account for any RAG independent recombination. 
Extrachromosomal assay with modified consensus 12/23 RSSs 
We used an established in vitro system in eukaryotic cells that measures 
recombination efficiency. Substrates were a gift from Dr. J Hesse and are 
described in detail in ref 127. As described above, the substrates carry an 
ampicillin (AmpR) resistance and upon a recombination event, resistance to 
chloramphenicol (CAT-R) is achieved as well. RMP41 fibroblast cells were 
transfected with full length Rag1 and the different Rag2 mutants with a 
recombination substrate as a read out. 48h post transfection we harvested the 
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cells and extracted DNA by phenol/chloroform extraction. DpnI-digested plasmids 
were then introduced into chemically competent E. coli and plated on ampicillin 
(100 μg/ml) and chloramphenicol (20-30 μg/ml). As a control we transfected the 
substrate alone without Rag1/2 to account for any RAG independent 
recombination. Absolute recombination efficiency was calculated by dividing the 
number of double resistant colonies by the total number of colonies (AmpR 
alone). The substrates contain the tested RSSs in inversion orientation meaning 
that double resistance can be acquired either by successful event (INV) or an 
unfaithful one creating a hybrid joint (HJ) product. HJ is generated upon a loss of 
one RSS. The cRSS that were tested possessed either a single nucleotide 
substitution in one RSS or a deletion of the whole heptamer or nonamer while the 
other is in intact consensus. 
Statistical Analysis 
A two-tailed unpaired t-test was applied for extrachromosomal recombination 
efficiency and for all other statistical analysis we used the Fisher exact test of 
independence. 
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Results 
 
RAG2FS/FS mice show increased cryptic RSS usage 
We wanted to investigate the cRSS usage by the FS allele in a more robust 
fashion since we only analyzed two tumors. Additionally we wanted to ensure 
that this phenotype is not dependent on p53 deficiency.  
To achieve that we used two approaches: 
1.  Intrageneic deletions in two genes; Notch1 and Bcl11b that are known to be 
mediated via the RAG complex and participate in lymphomagenesis (93,94). We 
examined genomic DNA from healthy thymi of wild-type RAG2 and RAG2FS/FS to 
avoid any effects of p53 deficiency. 
2. Aberrant rearrangement as seen in human lymphomas. Specifically the 
LMO2/Dd1 (138) and the Db1/TAL2 (139) that were tested in a cell-based assay 
with the RAG complex (137). 
DNA isolated from RAG2FS/FS mouse thymi showed a significant increase in 
recombination efficiency in both the Notch1 (p<0.03) and Bcl11b (p<0.003) genes 
than wild-type RAG2 (Fig.3.1A). Sequence analysis of the PCR products verified 
that they correspond to the correct genes (Fig3.1B+C). These aberrant events 
occur in a tissue of a non-tumorigenic mouse. Hence, in the case of a second hit, 
for example p53, these events can contribute and even initiate lymhomagenesis. 
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Figure	  3.1	  Intragenic	  deletions	  in	  Notch1	  and	  Bcl11b.	  Genomic	  DNA	  from	  thymocytes	  
of	  indicated	  genotypes	  was	  used	  in	  nested	  PCR	  to	  detect	  a	  12Kb	  and	  65kb	  deletions	  in	  
Notch1	  and	  Bcl11b	  genes	  respectively.	  A.	  Comparison	  between	  wild-­‐type	  and	  RAGFS/FS	  
mice.	  *	  p	  <0.03,	  **p<0.003.	  B-­‐C.	  Sequence	  analysis	  of	  the	  PCR	  products	  for	  Notch1	  (B)	  
and	  Bcl11b	  (C).	  First	  line	  represents	  the	  germline	  sequence	  with	  bold	  letters	  indicating	  
the	  cRSS	  from	  each	  side.	  Capital	  letters	  in	  the	  middle	  of	  the	  junction	  are	  N	  nt,	  Bold	  
capital	  are	  P	  nt.	  wild-­‐type	  n=1,	  RAG2FS/FS	  n=2-­‐4	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The same trend was observed with both the LMO2/Dd1 and Db1/TAL2 
extrachromosomal substrates in fibroblast cells (Fig.3.2 A+B). The RAG2FS 
mutant was significantly more competent in recombining these human cRSSs 
than FLR2 (3.5 to 5 fold with TAL2, pv<0.03 and LMO2 pv<0.05 respectively). 
These results both support our hypothesis that the C terminus of RAG2 inhibits 
usage of cRSSs as well as implying that illegitimate V(D)J recombination by the 
FS allele may provide an additional mechanism by which the lymphomas in 
RAG2FS/FS;p53-/- mice evolved. 
 
 
 
Figure	  3.2	  Recombination	  efficincies	  with	  human	  cRSSs.	  A.	  LOM2/Dd2	  and	  B.	  TAL2/Db1	  
substrates	  were	  transfected	  into	  RMP41	  cell	  line	  together	  with	  FLR1	  and	  indicated	  RAG2	  
version.	  No	  RAG	  is	  transfection	  of	  the	  substrate	  alone.	  Recombination	  efficiencies	  were	  
measured	  48h	  after	  transfection	  as	  described	  in	  methods.	  Pv	  is	  vs	  FLR2.	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The Dynamic between RAG2 and the RSS 
To better understand the role of the RAG2 C terminus in illegitimate V(D)J 
recombination we decided to examine its ʻbehaviorʼ in vitro with different cRSSs. 
We used well-defined recombination substrates that differ from each other only in 
their RSSs (127, Fig.3.3 &3.4). Our approach was to compare recombination 
efficiency of full length RAG2 (FLR2) to RAG2 mutants that accelerate 
lymphomagenesis in a mouse model: RAG2 Core (84), RAG2FS (chapter 2) and 
RAG2Neut (Coussens M, unpublished). The latter mutant retains the RAG2 C 
terminus but has neutralized acidic residues in a.a 370-383 (74). Unfortunately 
the RAG2 Core study was not completed because the version that we used (a.a 
1-383) did not correlate with the mutation in the mouse as we discovered midway 
into the project (chapter 2).  
We selected five different extrachromosomal substrates with modified consensus 
RSS (Fig 3.4). All of those were previously used showing very low levels of 
recombination with wild-type RAGs (127). The RSSs in these substrates are 
oriented in an inversional configuration (FIG 3.3). Hence a positive readout can 
be the result of a faithful inversional event or an unfaithful one such as a HJ 
(detailed in Methods, Fig 3.5). 
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Figure	  3.3	  pJH299	  Plasmid.	  The	  vector	  is	  preented	  both	  as	  circular	  and	  linear	  for	  
convenience.	  Important	  regions	  are	  indicated.	  	  Different	  cRSSs	  are	  color-­‐coded	  and	  their	  
sequence	  is	  given	  in	  the	  Fig.6.	  The	  direction	  of	  the	  arrow	  indicates	  the	  direction	  of	  the	  
RSS.	  Blue	  RSSs	  are	  the	  consensus	  12/23	  RSS.	  Ori	  –	  origin	  of	  replication,	  CAT-­‐R	  
chlorophenicol	  resistance,	  AmpR	  ampiciline	  resistance.	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Figure	  3.4	  List	  of	  RSS	  in	  pJH299	  plasmid.	  Consensus	  12/23	  RSS	  are	  indicated	  in	  blue.	  
Tested	  cRSS	  are	  annotated	  and	  changes	  from	  the	  consensus	  12/23	  RSS	  are	  indicated	  in	  
red.	  ‘Fortuitous	  cRSS’	  are	  cRSSs	  that	  were	  used	  instead	  of	  the	  tested	  cRSSs.	  Rev12	  RSS	  –	  
Tested	  12	  cRSS	  in	  the	  opposite	  orientation.	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Figure	  3.5	  pJH299	  recombination	  products.	  Without	  RAG	  activity	  the	  transcription	  
terminator	  sequence	  does	  not	  allow	  expression	  of	  the	  Chloramphenicol	  	  (CAT-­‐R)	  
antibiotic	  resistance	  gene.	  Upon	  rearrangement	  this	  region	  is	  either	  flipped	  (inversion)	  
or	  lost	  (HJ)	  allowing	  transcription	  of	  the	  antibiotic	  resistance	  gene.	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Our theory was that a mutant RAG2 C terminus would lead to increased 
recombination efficiencies and higher HJ formation with cRSS. If this was to 
materialize, the type of cRSSs we chose will assist us in better understanding 
some mechanistic aspects of these erroneous events.   
1. A 12 or 23 RSS with only a heptamer: to test for role of the nonamer because 
a lot of cRSSs usually have poor nonamer conservation than heptamer, if at all.   
2. A 12 or 23 RSS with modified heptamer, CATAGTG: to test the requirement for 
a ʻCACʼ in the presence of the mutants. If the RAG2 mutants are not as strict as 
wild-type RAG2, this can affect the identification of cRSSs in our tumor data.  
3.  A 12RSS with only nonamer: to test whether a perfect nonamer, on its own, 
can participate in recombination. Biochemical studies showed that an oligo with 
only a nonamer could be nicked but not fully cleaved (136). It is of interest 
whether the RAG2 mutants might overcome this block. (23RSS with only 
nonamer was not tested, a decision based upon our results with a heptamerless 
12RSS, as detailed later). 
As a first step we needed to assess the recombination efficiency of the RAG2 
mutants with the inversional substrate harboring 12 and 23 consensus RSSs. We 
found that both RAG2FS and Neut mutants have increased recombination 
efficiency that is significantly better than a FLR2 (Fig 3.6B). This was not due to a 
hyper recombination activity of the mutants because examination of deletion 
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events, for instance, showed similar recombination efficiency (Fig 3.6A). We then 
compared the ratio of inversion (INV) vs HJ junctions generated. Again, both 
mutants had elevated HJ recombination events vs FLR2 (pv<0.003, Fig 3.6C). 
We therefore deduced that the C terminus of RAG2 inhibits unfaithful 
rearrangements that can lead to loss of DNA material. This result is in 
accordance with increased HJs seen in splenocytes from RAG2 Core mice (84). 
	  
Figure	  3.6	  pJH299	  recombination.	  	  Inversional	  	  (pJH299)	  and	  deletional	  (pJH290)	  
substrates	  were	  transfected	  into	  RMP41	  cell	  line	  together	  with	  FLR1	  and	  indicated	  RAG2	  
version.	  ‘No	  RAG’	  is	  transfection	  of	  the	  substrate	  alone.	  A+B.	  Recombination	  efficiencies	  
were	  measured	  48h	  post	  transfection	  as	  described	  in	  methods.	  C.	  PCR	  was	  carried	  out	  
to	  identify	  individual	  recombination	  events	  via	  inversion	  or	  HJ	  resolution.	  8	  PCR	  
products	  from	  each	  RAG2	  version	  were	  verified	  by	  Sanger	  sequencing.	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The significant difference in recombination efficiency with the RAG2 mutants 
ruled out straightforward comparison of absolute recombination ability between 
the different RAG2 mutants when using various cRSSs. To overcome this hurdle 
we had to normalize the absolute recombination result obtained with the tested 
cRSS to that of consensus RSSs for each RAG2 version.   
Testing the different cRSSs we saw that all RAG2 versions have the same 
recombination efficiencies and that they can recombine a modified 12RSS better 
than a modified 23RSS (Fig 3.7). Comparing 12 to 23 RSS, Neut showed a 
significant difference throughout the analysis; FS was variable and FLR2 showed 
no significance. The lack of significance stems from the large standard deviations 
caused by the variability between experiments, as these are rare events. 
Nonetheless, as observed from the graphs the trend exists. Hence, it appears 
that 1) The C terminus of RAG2 does not affect RSS specificity and 2) A modified 
23RSS results in lower recombination efficiency than a modified 12RSS. This 
phenotype, though not dependent on the C terminus, is exacerbated when 
mutated. However, the difference between the 12 and 23 RSSs turned out to be 
more complex than we initially thought (described later). 
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Figure	  3.7	  Recombination	  efficiency	  with	  different	  cRSSs.	  cRSSs	  substrates	  were	  
transfected	  into	  RMP41	  cell	  line	  together	  with	  FLR1	  and	  indicated	  RAG2	  version.	  ‘No	  
RAG’	  is	  transfection	  of	  the	  substrate	  alone.	  Recombination	  efficiencies	  were	  measured	  
48h	  after	  transfection	  as	  described	  in	  methods.	  A.	  Heptamer	  only	  substrate,	  the	  partner	  
RSS	  is	  always	  a	  consensus	  one.	  B.	  Nonamer	  only	  12	  RSS	  the	  partner	  23RSS	  is	  a	  consensus	  
one	  C.	  mHeptamer	  RSS,	  the	  partner	  RSS	  is	  always	  a	  consensus	  one.	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We next wanted to know whether the different RAG2 versions might change the 
ratio of INV to HJ when encountering different cRSSs. To that end we sequenced 
over 300 junctions from the different substrates and mutants. This approach 
turned out to be very informative, not just for our initial question, but also for 
understanding other aspects of the recombination process. 
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For clarity I grouped the results as 12 vs 23 cRSSs:  
23 RSS modifications with consensus 12RSS: 
The different versions of RAG2 behaved similarly with altered 23RSSs (Fig 3.8 
B+D). Total HJ formation increased for FLR2 and FS but was not significantly 
different vs the one observed with 12/23 consensus RSS (Table 4).  A significant 
difference was seen only with the mHeptamer 23 RSS (CATAGTG) for FLR2 and 
FS but not Neut. However, this result was not consistent across the RAG2 
versions or with the other cryptic 23 RSS excluding a meaningful interpretation of 
its significance. Thus, it seems that overall 23 cRSS usage by the various RAG2 
versions does not result in increase in unfaithful recombination events. 
The sequence analysis revealed more than just junctional resolution. In the case 
of the ʻheptamer only 23RSSʼ half of the recombination events on average 
recombined using only a heptamer while the other half recognized the heptamer 
in an opposite orientation resulting in a coding joint (Fig 3.8B). With mutated 
heptamer 23RSS almost 100% of all recombination used this atypical heptamer 
(Fig.3.8D). These data suggest that the RAG complex, independent of whether 
the RAG2 C-terminus is present or absent, behaves differently in respect to the 
changes in the RSS regions. A very poor heptamer is better tolerated than a 
complete absence of a nonamer in a recombination event. 
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Figure	  3.8	  Sequence	  analysis	  of	  junction	  with	  tested	  cRSSs.	  Colonies	  exhibiting	  double	  
resistances	  were	  grown	  and	  Sanger	  sequenced.	  Calculation	  was	  done	  out	  of	  total	  events	  
for	  each	  situation.	  A.	  heptamer	  only	  12RSS,	  B.	  heptamer	  only	  23RSS,	  C.	  mHeptamer	  
12RSS,	  D.	  mHeptamer	  23RSS,	  E.	  Nonamer	  only	  12RSS.	  	  N	  indicates	  the	  number	  of	  
junction	  sequenced.	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Table	  4.	  .	  Junctions’	  resolution	  with	  the	  tested	  cRSS.	  	  Inversional	  (INV)	  versus	  hybrid	  
joints	  (HJ)	  were	  assessed	  by	  Sanger	  sequencing.	  Only	  junctions	  form	  pJH299	  were	  
assessed	  via	  PCR	  and	  several	  were	  validated	  by	  Sanger.	  The	  junctions	  are	  grouped	  by	  12	  
or	  23	  tested	  cRSS	  tested	  and	  compared	  to	  consensus	  RSSs	  (pJH299).	  Absolute	  number	  
and	  percentage	  are	  presented.	  *	  Significant	  increase	  in	  HJ	  with	  mHEptmaer	  (pv<0.05)	  
but	  not	  heptamer	  only	  tested	  cRSS.	  
 
12 RSS modification with consensus 23RSS 
As seen for the 23RSS, the ratio between the INV/HJ using different 12RSSs did 
not change when compared to consensus ones (Table 4). Nonetheless, unlike 
the cryptic 23RSSs, modification in the 12RSS revealed a distinctive behavior of 
the FS mutant (Fig 3.8 A+C+E).  
Using a ʻHeptamer only 12RSSʼ we found that FLR2 and Neut used this cRSS in 
46% and 37% of recombination events respectively, while the FS used it 
significantly less in only 14% of the time (pv<0.02, Fig 3.8A). All other 
recombination events were due to other cryptic 12RSSs comprised of various 
fortuitous cRSS in the plasmid, and the tested cRSS itself used in the opposite 
orientation. The decreased usage of ʼHeptamer only 12RSSʼ by the FS mutant 
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implies that in the absence of the C terminus the existence of identifiable 
nonamer is important to allow recombination.  
The results we observed for FS with a mutated heptamer on 12RSS were the 
opposite with regard to other cRSS usage (Fig 3.8C). The FS was able to utilize a 
poor heptamer, the tested cRSS, for 90% of recombination events. The inability 
to discriminate a ʻCACʼ from ʻCATʼ was most profound with FS (p<0.03 vs Neut 
and p<0.09 vs FLR2 where this result was 1 junction away from significance). In 
the first situation, when a perfect heptamer with no nonamer was tested, the FS 
mutant preferred to recombine different cRSS all together. However, when given 
a very poor heptamer with a perfect nonamer it recombined it very efficiently. 
Though the substrate had a very poor heptamer, some sort of a heptamer is 
needed. Analysis of ʻNonamer only 12RSSʼ showed that all mutants underwent 
recombination using a fortuitous cryptic 12 RSS in the plasmid (Fig 3.8E). In 
aggregate, the data from cryptic 12RSSs show that in the absence of the C 
terminus the existence of identifiable nonamer, even on the expanse of a perfect 
heptamer, is important to allow recombination.  
Our analysis revealed two additional intriguing features that will be discussed in 
the next section. First, a difference in handling the tested 12 or 23 RSSs. The 
spectrum of fortuitous cRSSs used with the tested 12 or 23 RSSs was 
significantly different (p<0.0001). In the ʻHeptamer only 23RSSʼ substrate all the 
fortuitous cRSSs stemmed from reading the tested RSS in the opposite 
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orientation. In the ʼHeptamer only 12RSSʼ substrate more than half of cRSSs 
were derived from different regions in the vector (Fig 3.8A vs B). The second 
feature relates to recognizing the heptamer in an opposite orientation. Given the 
ʻHeptamer onlyʼ substrates (Fig 3.8 A+B), the RAG complex used the heptamer 
in both orientations. However, in the case of a mutated heptamer (Fig 3.8 C+D), 
only 2/132 junctions were formed with the heptamer in the opposite orientation.  
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Discussion 
Illegitimate V(D)J recombination was reported in multiple human and mouse 
lymphomas (91-95). These events can lead to genomic lesions of all kinds and 
contribute to or even initiate tumorigenesis. Therefore, a deep understanding of 
the mechanisms that cause them is very important to enable us to devise ways to 
inhibit them. 
Our results show that the C terminus of RAG2 plays a very important role in 
preventing aberrant rearrangements by the RAG complex. Such events were 
found both lymphomas from RAG2FS/FS;p53-/- and healthy thymi from RAG2FS/SF 
mice. Almost a 100% of tested mice had an intrageneic deletion in Nocth1 and 
Bcl11b genes. This means that erroneous events are not just random event that 
were positively selected in a tumor, but are a cause of the RAG complex activity. 
One possibility for an increase in off target events in the absence of the RAG2 C 
terminus is relaxation in RSS specificity. This was shown to be the case in 
biochemical studies comparing FLR2 and Core RAG2 with consensus or 
suboptimal RSS (140). However, our functional examination of several cRSSs 
with different RAG2 versions showed that the C terminus of RAG2 does not 
seem to profoundly or systematically relax specificity in our system. This was 
also the result of a comprehensive analysis comparing cRSSs between p53-/- and 
RAG2del352/del352;p53-/- lymphomas (Mijuskovic M, in preparation). Thus, the 
frequent illegitimate recombination we observed in our mouse models were due 
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to other reasons. One explanation can be a difference in chromatin accessibility 
that allows more and/or different regions of the DNA in truncated RAG2 mice to 
be cleaved and recombined. For example, a pre-oncogene can be accessible for 
recombination in the mutated mice but not in wild-type mice (with FLR2) leading 
to the accelerated lymphomas. A second reason might be differences in the 
epigenetic make up landscape. As mentioned earlier, the PHD domain of RAG2 
inhibits recombination unless H3K4me3 is present (135). The FS allele lacks the 
PHD domain overriding this level of regulation resulting in more erroneous 
recombination. This might be the case with the LMO2 and TAL1 cRSSs we 
tested because extrachromosomal substrates normally have high levels of 
H3K4me3 (141,142). A third cause can be variation in developmental stage 
between wild-type RAG2 and mutant RAG2 mice. The latter are blocked at the 
pro to pre T/B cell stage. Hence, the RAG complex presence is lengthen because 
the cells are trying to rearrange the antigen receptor locus and progress. This 
can statistically increase the chance of cleavage at off target sites in these cells. 
An argument against this is the fact that Core RAG1 mice, which exhibit the most 
sever block in that pro to pre stage, when crosse to p53-/- are devoid of the 
genomic instability seen in RAG2del352/del352;p53-/- (84). Lastly, it might be that 
FLR2 activity is similar to the truncated RAG versions in terms of recognition and 
cleavage of cRSSs but not joining and this is why we cannot detect various 
structural variants in wild-type mice. The work presented here in chapter one 
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support this idea via the ability of the FS allele, but not wild-type RAG2, to repair 
ends via the ʻa-NHEJʼ pathway(s). 
Our cRSS analyses shed light not only on the role of the RAG2 C terminus in 
illegitimate V(D)J recombination but also on aspects of V(D)J recombination in 
general. First, our results strengthen the notion that a functional RSS is a 
summation of all its regions rather than each part individually. None of the 
fortuitous cRSS used had a perfect heptamer nor nonamer. Second, our data 
support the model of initial synapsis with a 12-RSS by the RAG complex, 
followed by capture of a 23RSS (143). Only the tested cryptic 12RSSs, but not 
the 23RSSs were underutilized in favor of a whole different cRSS. This points to 
the importance of a good 12 RSS probably because it indeed initiates the 
recombination reaction. Once a good 12RSS is captured, greater variations on a 
23RSS can be tolerated. One can argue that the usage of other cryptic 23RSS is 
not observed because the plasmid is devoid of them. However, at least 2/8 
cryptic 12RSS can also qualify as a cryptic 23RSS. Additionally, capture of a 12 
RSS in the absence of a C terminus is highly dependent on an identifiable 
nonamer. In the presence of FLR2, the nonamer does not have much impact on 
the recombination process. This is also seen in our tumor data in which the 
heptamer is much more conserved than the nonamer in the cRSSs. Unlike with 
FLR2, in the absence of the C terminus an RSS with a strong nanomer will 
prevail. This suggests that good contact of the RAG1 with the DNA in that 
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scenario is critical, probably compensating for a signal given by the C terminus to 
proceed with recombination. Third, we show data that can relate to the RAG 
complex positioning on the RSS. In the presence of a strong nonamer a 
heptamer can only be read in one orientation. We postulate that the RAG 
complex is becoming ʻlockedʼ in a certain configuration that directs its alignment 
with the heptamer. This might not be influenced by the RAG2 because contact 
with the nonamer is mediated via RAG1 (69,144). Not having a nonamer allows 
more flexibility in the RAG complex positioning on the DNA so a heptamer can be 
read in both orientations. This is probably due to the palindromic nature of the 
heptamer; the RAG complex cannot tell one way from the other, as there is no 
polarity to the sequence. However, this flexibility might come with a price of 
complex stability with the DNA because almost half of the junctions in ʻheptamer 
only 12RSSʼ were via fortuitous cRSS in the plasmid. It might be that the RAG 
complex, in the presence of a good heptamer, ʻscansʼ the DNA for a nonamer or 
there are multiple steps of association and disassociation until a permissive 
configuration is achieved. Regardless of the mechanism, the ability to utilize a 
heptamer in both orientations is very hazardous for genome integrity as such 
heptamer can be a partner as a 12 or 23 cRSS.  
We wanted to examine if cRSS found in our tumors agree with our assumption 
that a good nonamer on 12RSS is important in the presence of the FS allele. We 
found most of our annotated cRSSs to agree with it. Only one junction (#21) 
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might not qualify while another junction (#30) that we did not consider to be 
mediated via cRSS might actually be one when looking at their nonamers (Table 
3).  
The increase in illegitimate V(D)J recombination in the absence of the RAG2 C 
terminus is not due to relaxation in RSS specificity and can be due to a variety of 
other reasons as mentioned above that should be explored experimentally. 
Nonetheless, we did observe that RAG2 with truncated C terminus prefers usage 
of cRSSs with identifiable nonamers.  
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CHAPTER 4 
Discussion and future directions 
 
Findings overview 
In this body of work we observe that repair pathway choice is enforced during 
V(D)J recombination in vivo, in both c-NHEJ-proficient and c-NHEJ- deficient 
mice, and that  RAG2's C-terminus is critical for this regulation. Surprisingly, we 
discover that the way in which a-NHEJ handles broken DNA ends is strongly 
context-dependent: signal joints show reported features of a-NHEJ, whereas 
coding joints do not. In fact, joining of RAG-generated coding ends by a-NHEJ in 
our system produced junctions that were largely indistinguishable from those 
arising from c-NHEJ. Whole genome sequencing of lymphomas derived from 
RAG2FS/FS;p53-/- mice showed that half of the genomic lesions similarly lack 
distinctive features of a-NHEJ. However, some lesions, including those in known 
oncogenes, appear to arise from ectopic recombination between DNA sequences 
fortuitously resembling RSS. Such genomic lesions are seen in models with wild-
type RAG2, but they are both increased and involve, for the most part, distinct 
genomic regions in our RAG2 C terminally truncated mice. This difference is not 
due to relaxation in RSS specificity by the truncated RAG2 and may be due to 
other reasons or combination there of, that need to be further investigated. 
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Understanding alternative NHEJ 
Despite great efforts from multiple labs for almost a decade to try to define 
aNEHJ, we are still in the dark. The best definition to date is ʻrepair in the 
absence of c-NHEJʼ. The lack of consistent phenotypes across different models 
(e.g ku80 vs XRCC4 deficiency (31), V(D)J vs CSR) hinders our ability to define a 
pathway or even multiple pathways distinct from c-NHEJ. The work described 
here and others suggest that ʻa-NHEJʼ probably represents different repair 
outcomes depending on the environment of the breaks, thus there are different 
flavors of NHEJ (145). For example, coding joints retrieved from our 
RAG2FS/FS;KU80-/- mice could have been generated via PARP1 in combination 
with the rest of the c-NHEJ machinery that is present in the cell (47). This might 
also be the reason our junctions looked similar to junctions formed by c-NHEJ. It 
would be interesting to test this hypothesis with our double mutant 
RAG2FS/FS;Ku80-/-  mice by crossing them to PARP1 null mice to observe if we 
can still rescue V(D)J recombination.  
The importance of defining and understanding a-NHEJ repair has clinical 
implications. If indeed a-NHEJ is the dominant repair mechanisms leading to 
tumorigeneic genomic lesions, identifying the proteins that facilitate it would be 
valuable for cancer treatments and gene therapy. Moreover, it is also necessary 
to understand what, if any, are the physiological roles and normal functions of the 
a-NHEJ repair pathway. 
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Increase in proteins associated with a-NHEJ, PARP1 and Ligase III, has been 
reported in antiestrogen-resistant human breast cancer (54), positioning such 
factors as potential therapeutic targets. Indeed, such tumor cells were eradicated 
by a combination of PARP1 and DNA ligase III inhibitors (54). Interestingly 
though, single inhibition of either one was not enough to confer significant toxicity 
(54). PARP1, a potential a-NHEJ factor, is also being clinically tested in patients 
with breast cancer that are deficient in HR due to mutations in BRCA1/2 genes 
(146). Although this treatment looks promising in certain patients, the exact 
mechanism that underlines this effect is still unclear (146). One explanation, in 
the context of a-NHEJ, would suggest that in the absence of HR, DSBs that are 
generated could become occupied by PARP1, turning on a-NHEJ repair leading 
to genomic lesions that contribute to tumorigenesis (9,10,54). Hence, inhibiting 
PARP1 would leave these breaks unrepaired directing the cell to apoptosis. 
Alternatively inhibiting a-NHEJ could increase c-NHEJ repair, which was shown 
to suppress tumorigenesis (9,10). One study showed that PARP1 inhibitors 
indeed activated c-NHEJ, however, this activation led to genomic instability that 
then sensitized the lethality in HR deficient tumors (147). The PARP inhibitors 
example demonstrates the complexity we are facing when trying to decipher the 
role of a-NHEJ in tumorigenesis. While HR deficient breast cancer cells benefited 
from treatment with PARP inhibitors alone the antiestrogen-resistant tumors 
required combined therapy with PARP1 and ligase III inhibitors (53,147). This 
supports the idea that a-NHEJ probably encompasses several pathways 
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(68,148). Moreover, in HR deficient cells the c-NHEJ repair mechanism was 
responsible for genomic instability (147). Hence, a clinical approach to shift DNA 
repair from a-NHEJ to c-NHEJ might not always be beneficial. Notably, PARP 
inhibition was beneficial in less than 50% of HR deficient breast cancer cells 
implying that other factors might need to be targeted to inhibit this tumor (148). 
Further investifgation of a-NHEJ would most likely uncover some of these factors. 
So far, most of the factors associated with a-NHEJ also participate in other 
established repair mechanisms (e.g PARP1 in base excision repair). Therefore, a 
more detailed investigation of a-NHEJ might discover specific factor(s) that could 
then be inhibited to eliminate collateral damage caused to other repair 
mechanisms. 
 
Gene therapy is another field that would benefit from better understanding of a-
NHEJ. As there is no room for error when manipulating the genome it is 
imperative that we pursue the deepest knowledge possible.  
ʻReplacementʼ of a damaged gene with a corrected version of itself, or 
ʻreplacementʼ of a good gene with a mutated one (to study the geneʼs function), 
are the most straightforward applications of gene targeting. These processes are 
thought to benefit from inhibiting NHEJ repair in favor of HR to decrease random 
integrations of the vector into the genome (149,150). In this scenario it is not 
enough and even dangerous to block only c-NHEJ. In the absence of c-NHEJ, a-
NHEJ is turned on and can promote chromosomal aberrations (9,10,37,45,48). 
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Thus, while trying to correct a specific mutation we might actually be promoting 
tumorigenic event(s).  
Another application is targeted disruption of a gene that promotes disease, like 
CCR5 in HIV infection (151). This process is dependent on c-NHEJ repair to 
create micro-changes in the gene to render it nonfunctional (151). Just like in the 
previous scenario, suppression of a-NHEJ would reduce the chances of gross 
genomic aberration upon DNA cleavage by the nuclease. This scenario 
emphasizes the need to fully understand whether a-NHEJ is a distinct repair 
pathway from c-NHEJ or whether it is a combination of pathways that might 
share components with the c-NHEJ repair machinery. If the latter is true then 
using this methodology might be more challenging than initially thought.  
 
Until we better understand a-NHEJ repair pathway(s), perhaps a functional 
definition is more suitable; ku80 dependent, PARP1 dependent etc. In this case 
each group would comprise all possible outcomes of that condition. Either 
approach wiould also disqualify, once and for all, certain junctional quality as a 
feature of one repair pathway. In support of such an approach is a recent paper 
showing that even in the absence of Ku80 the majority of DSBs in a human cell 
line were repaired via Ligase IV (152).  
There are different experiments that can be pursued to gain deeper 
understanding of what a-NHEJ is/are. Taking a biochemical approach, we can 
test purified DNA repair proteins for their end joining activities. In this fashion we 
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can control the order or composition of the proteins and also test different types 
of breaks (I-Sce vs V(D)J). However, numerous disadvantages exist (not all 
proteins can be purified, impaired protein folding, protein modification, no 
chromatin etc) that ultimately might not grant us with a clearer picture. 
A different approach is to carry out RNASeq of different cancer types that show 
upregulation or downregulation of factors associated with a-NHEJ or c-NHEJ 
respectively (52,54). Comparison of these data sets to data from a control, non-
tumorigenic tissue might result in discovering new proteins that participate in a-
NHEJ and/or shed a different light on known proteins that were not initially 
considered to be involved in a-NHEJ.  Alternatively, we can perform whole 
exome sequencing on these tumors and look for mutations that can confer a 
selective advantage. Our focus would be on DNA repair genes and additional 
genes that their activity is still not fully elucidated but might be participating in 
DNA repair. Potential factors identified via RNASeq or the exome sequencing 
would be followed by a validation stage to eliminate false positive calls. To that 
end various established end-joining assays (e.g I-Sce, V(D)J recombination, CSR 
etc) can be performed to test whether the factor indeed affects end-joining repair. 
Western blot and immunoprecipitation experiments would be used to 
demonstrate expression patterns and possible interactions that can assist in 
elucidating mechanistic elements. Lastly, animal studies with over expression or 
knockdown of the selected factors should be considered in order to study the 
targeted factor in a more physiological setting. 
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Additional experiments that should be explored include characterization of cells 
deficient for both c-NHEJ and associated a-NHEJ factors. Zhang et al showed 
that translocation events were still occurring in cells deficient for Ku70 and CtIP 
(37), implying that additional factors or yet, an unidentified combination of known 
factors can promote such aberrant end joining. This approach should be tested 
using different combination of deficiencies in known DNA repair factors. In turn, 
such data would generate a matrix of potential a-NHEJ cascades/platforms. To 
illustrate that, we can think of the following scenario: cells deficient for ku70 & 
ligase III or ku70 & CtIP exhibit equal translocation frequencies, while cells 
deficient for all three factors show reduced translocation frequencies. This result 
would suggest that in the absence of ku70, CtIP and ligase III function in different 
a-NHEJ repair pathways. Any meaningful combination of deficient cell lines 
should be subjected to microarray analysis to evaluate changes in the 
transcriptome versus wild-type and singly deficient cells to illuminate factors that 
might participate in a-NHEJ repair. As translocations are not the only abnormal 
events in tumors, exploring end joining substrate with a deletion configuration 
would also be valuable. Comparison of factors identified with the translocation 
substrate with that of the deletion substrate could teach us about the 
mechanism(s) that drive(s) these different lesions and possibility aid in cancer 
treatment. One can theorize that translocation events might be driven by a-NHEJ 
repair while deletion events may be equally driven by classical or alternative 
NHEJ repair. 
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Lastly, our results from RAG2 mouse knockins (RAG2FS/FS, RAG2del352/del352) 
show that these mutants have the ability to access a-NHEJ repair pathway(s) 
both in c-NHEJ proficient and deficient settings. However, we do not know what 
factors allow or participate in such repair. It would be of interest to cross our 
knockin mice to mice deficient in potential a-NHEJ factors and to assess coding 
and signal joint formation. Work done previously in our lab showed that NBS1 is 
needed for a-NHEJ repair by the RAG2 FS mutant on an extrachromosomal 
substrate (153). Thus, we can theorize that crossing of RAG2FS/FS to a 
hypomorphic version of NBS1 would decrease both aberrant signal joint 
formation and interchromosomal rearrangements between different TCR loci that 
are considered indicative of a-NHEJ. Such a result would strengthen the role of 
NBS1, and perhaps the MRN complex as a whole, in a-NHEJ repair (43,153).  
 
In the pursuit to improve oneʼs life through cancer treatment or gene therapy it is 
vital to gain better insights of what is/are a-NHEJ repair. The knowledge 
accumulated through experiments described above and others would assist us in 
designing better strategies to achieve this goal. 
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Tumorigenic anecdotes through the lens of whole genome 
sequencing 
There are various types of genomic lesions ranging from point mutations to large 
gross abnormalities like translocations. There is no linear correlation between the 
size of the lesion and its damage to the cell or the organism as a whole. For 
example, a point mutation in a critical gene can be more deleterious than a 
reciprocal translocation. Whole genome sequencing (WGS) of two tumors in this 
study raises several interesting insights regarding the process of 
lymphomagenesis. 
1) As whole genome sequencing is a luxury of the last few years, a lot of the 
attention in cancer research was initially concentrated on identification of 
translocations by cytogenetic analysis. Technically, micro or small lesions are 
difficult to impossible to identify. Abnormalities such as deletions, insertions, 
duplication and inversions were generally unaccounted for. As a result, great 
efforts were aimed at identifying and characterizing translocations formation 
(10,33,37,48,68). However, as data from WGS is accumulating it appears that 
intra-chromosomal genomic lesions, specifically deletions, are substantially more 
frequent in lymphomas than are translocations (Mijuskovic M, in preparation, 97). 
67% of lesions found in our RAG2FS/FS;p53-/- lymphomas were deletions, 27% 
inversions and only 6% translocations. Indeed, detection of lesions by WGS is 
limited by depth of coverage and it is possible that more translocations exist that 
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are not detected. However, it implies that these translocations are not particularly 
advantageous for the tumor and are probably more of random (ʻpassengerʼ) 
lesions than oncogenic ones.  
 
2) Capture of different types of lesions might also shed a different light on the role 
of c-NHEJ in tumoregenesis. This repair mechanism is thought to suppress 
genomic lesions due to translocations seen in c-NHEJ deficient backgrounds 
(9,10). Moreover, sequences of these translocations showed increased usage of 
microhomologies associated with a-NHEJ (9,11,12). In this study, looking at 
deletional events retrieved from c-NHEJ proficient animals the majority of 
junctions looked similar to ones formed via c-NHEJ repair. On the other hand, 
inversional events exhibited short microhomolgies associated with a-NHEJ in 
80% of the junctions. (We could not compare translocations because we only 
captured two translocation events and they were devoid of microhomologies). 
Assuming that microhomologies are indeed a feature that characterizes a-NHEJ 
(which is not the case as shown in this study) this repair mediated only part of the 
genomic lesions. All other events, including translocations, could not be 
confidently assigned to any repair pathway. As a result, the role of c-NHEJ in 
tumorigenesis must not be underestimated because deletions, the majority of the 
genomic instability, could have been mediate by c-NHEJ rather than a-NHEJ. 
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3) The granular analysis provided by sequencing of the lesionsʼ breakpoints also 
opened a great window to understand mechanisms of tumorigenic 
rearrangements. For example, RSS-like sequence or presence of an AID 
recognition site in the vicinity of resolved ends might provide strong evidence or 
footprints of the process that facilitated it. Sequence analysis of 51 human ETV6-
RUNX1 ALL determined that illegitimate RAG activity was the predominant driver 
leading to transformation (97). A comprehensive analysis of 11 thymic 
lymphomas done in the our lab show that at least 30% of aberrant lesions are 
mediated via illegitimate V(D)J recombination (this work and Mijuskovic M, in 
preparation) because we could identify cRSSs in the vicinity of the break. Some 
of the genes involved in these rearrangements are already implicated in 
tumorigenesis while others have not been. Hence, such analyses have the power 
to uncover mechanisms as well as potential new tumorigenic genes that were not 
considered before. These new genes may become a diagnostic tool and even 
potentially a therapeutic target. Notably, by looking only at cRSSs, we might be 
underestimating the involvement of the RAG complex. It has been shown that the 
RAG complex could also cleave a non-canonical DNA structure (non-B 
DNA)(154). The t14;18 translocation in follicular B cell lymphoma is thought to 
arise through cleavage by the RAG complex at a non-B DNA structure on 
chromosome 18 (154). Hence, it is probable that the RAG complex may have 
mediated some of the other lesions that were devoid of cRRSs. 
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4) The evidence of aberrant V(D)J recombination in genomic lesions ties us back 
to the question of c-NHEJ and tumorigenesis. It is established that the c-NHEJ 
repair machinery joins V-D-J ends. Thus, V(D)J ends generated outside of the 
antigen receptor loci are more than likely to be joined by this repair mechanism 
as well. Hence, the aberrant V(D)J events we observed position c-NHEJ as a 
repair pathway that can predispose to tuomoregensis much like a-NHEJ is 
thought to be. Moreover, 50% of these events involved genes implicated in 
tumorigenesis further supporting the contribution of c-NHEJ repair to the 
lymphomas in our mouse models. 
 
5) The substantial off target activity of the RAG complex, genome wide, should 
be a warning sign when attempting gene targeting. Several nucleases such as 
Transcription activator-like effector nuclease (TALEN) and Zinc Finger Nucleases 
(ZFN) are being studied for genome engineering. Although they are sequence- 
specific, like the RAG recombinase, off target activity of these nucleases has 
been reported (155). However, these off target sites were predicted a priori either 
by identifying sequence homology to a different gene or by prediction algorithms 
(155). In light of our WGS results, such biased approaches to test for off target 
activity are neither satisfactory nor prudent. Hence, it is of great importance that 
WGS be performed on cells engineered with these nucleases to assess, in an 
unbiased fashion, their full potential for off target activity. Preliminary work in our 
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lab show that WGS of a single clone engineered with TALENs revealed 
numerous unpredictable off target sites (Lindsay C, Roth lab). 
 
WGS in our studies and ones carried out in human lymphomas (97) 
demonstrates its importance in better understanding tumor pathology. Hence, it 
might be valuable if tumors that share common features would be sequenced to 
try to identify patterns of genomic aberrations that can be informative. Once a 
large enough data set is compiled we then could screen for only targeted variants 
that were deemed important. WGS can also assist in understanding cancer 
evolution and metastasis. Sequencing of a tumor upon diagnosis and comparing 
it to tumor that reemerges could shed light on acquisition of chemo-resistance. 
Another scenario can be a comparison of primary vs. metastatic foci to 
understand changes in the tumor that conferred metastasis. It is obvious that in 
parallel to this genomic approach, important genomic lesions should be 
investigated biologically via microarray analysis, for example, to explore if and 
how they influence the biology of the tumor. Such analysis would help determine 
whether a certain variant can be used as a diagnostic and/or therapeutic target. 
From a clinical pint of view, WGS is still an expansive endeavor, yet 
advancement in technology and big data analysis are continuously decreasing 
cost and turnover time. Implementing WGS in a clinical setting has other 
challenges: quality of specimens, training health care professionals, meaningful 
communication of results to physicians/patients, and standardizing an 
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appropriate use of the technology. Nonetheless, if WGS is essential to provide 
the optimal care we should not let these challenges be more than a temporary 
obstacle.  
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Supplementary information	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Figure	  S1.	  Signal	  joints	  sequences	  from	  wild-­‐type	  and	  RAG2FS/FS	  mice	  
A.	  SJ	  from	  Vβ14-­‐Dβ1.	  B.	  SJ	  from	  Vδ5-­‐Dδ2.	  C.	  SJ	  from	  Vβ8.3-­‐Dβ1.1	  D.	  SJ	  from	  Vβ10-­‐Dβ1.	  
Germ-­‐line	  sequence	  of	  each	  locus	  is	  shown	  at	  the	  top.	  Capital	  letters	  indicate	  the	  RSS	  
and	  small	  letters	  were	  indicted	  are	  coding	  end	  region.	  Capital	  letters	  in	  the	  middle	  of	  
the	  junction	  indicate	  N	  nt,	  deletions	  are	  indicated	  in	  parentheses,	  small	  letter	  indicates	  
sequences	  from	  the	  coding	  region	  (miscleavage),	  capital	  bold	  italics	  are	  microhomology	  
and	  underlined	  blue	  are	  open	  shut	  junctions.	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Figure	  S2.	  Coding	  joint	  sequences	  from	  wild-­‐type	  and	  RAG2FS/FS	  mice.	  Whole	  
thymocytes	  or	  BM	  cells	  from	  2-­‐3	  mice	  were	  analyzed	  by	  PCR	  amplification	  of	  the	  
indicated	  loci	  followed	  by	  Topo	  cloning.	  Germ	  line	  sequence	  is	  indicated	  at	  the	  top	  of	  
each	  locus.	  Capital	  letters	  in	  the	  middle	  of	  the	  junction	  indicate	  N	  nt,	  capital	  bold	  are	  P	  
nt,	  deletions	  are	  indicated	  in	  parentheses,	  small	  letter	  indicates	  sequences	  from	  the	  
coding	  region	  (miscleavage).	  A.	  Vβ6/7/8-­‐Jβ2	  B.	  Vβ10-­‐Jβ2.1	  C.	  Vβ14-­‐J1.1.	  Blue	  and	  red	  
represents	  the	  ADRs	  D.	  Dβ2-­‐Jβ2	  	  (bold	  small	  letters	  represent	  the	  12	  RSS)	  E.	  Vh1783-­‐Jh4.	  
F.VH	  CDR3	  length	  distribution	  analyzed	  by	  CDR3	  spectratyping	  on	  spleen	  DNA	  (54).	  
CDR3	  length	  (bp)	  is	  plotted	  for	  wild-­‐type	  and	  RAG2FS/FS	  mice.	  Each	  symbol	  represents	  a	  
single	  rearrangement	  of	  J606.1-­‐JH2	  (left	  panel)	  or	  J558.82-­‐JH2	  (right	  panel).	  Each	  
column	  is	  an	  individual	  mouse	  of	  a	  given	  genotype	  (n=3	  per	  genotype).	  	  Horizontal	  bars	  
indicate	  the	  median	  CDR3	  length	  for	  all	  of	  the	  rearrangements	  sampled	  in	  a	  single	  
mouse.	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